Low-dose GLP-1 provider reviews

Microdose SKUTaking less costs no less

Named microdose products, each priced above the standard plan for the same drug.

Both figures are named Microdosing Therapy products, with no milligram stated: $149/mo semaglutide and $199/mo tirzepatide, each above the standard plan for the same molecule ($99 and $149/mo, the same at every dose).

Microdose SKU

A capped tirzepatide microdose that costs less than the full dose at every term.

A named Microdosing Tirzepatide capped at 1 mg/week: $169/mo on 12 months up to $189 on 3 months, against $280–$313 for standard tirzepatide on the same terms. No monthly microdose plan.

Microdose SKU

A named microdose protocol that costs more than its standard semaglutide.

$179/mo is a named microdosing protocol with no molecule, milligram or plan length stated; standard semaglutide is $99/mo on a 6-month plan before the new-patient discount.

Microdose SKU

A named microdose for each molecule, priced below its standard injection.

A named Microdose GLP-1 at $149/mo semaglutide and $199/mo tirzepatide with a two-month minimum and no milligram stated, against $199 and $299/mo for the standard injections month to month.

Microdose SKUTaking less costs no less

Sells a real microdose product for both molecules, at full-dose prices.

SkinnyRx does sell microdose injectables as their own products — and prices them above its own full dose. The microdose floor is $229 semaglutide / $319 tirzepatide on eight months, while the full-dose plans reach $199 / $299 on a twelve-month commitment the microdose line is not offered on.

Microdose SKUTaking less costs no less

A separately titled microdose whose ladder matches the full dose rung for rung.

The microdose is a separately titled product whose ladder is identical to the full-dose one rung for rung — $159/$149/$129/$119 on semaglutide either way, $249/$229/$189/$179 on tirzepatide either way. Only the struck-through anchor above the ladder differs between the two products. No milligram figure is published for what any of it buys.

Microdose SKU

Sells a microdose as a product in its own right, not as a plan you underuse.

$116/mo is the named Microdosed Tirzepatide product — at its longest plan length. The list rate is $279, and the rate you get depends on how long you commit.

Microdose SKU

An explicit microdose track — billed in months that are four weeks long.

The Microdose GLP-1Rx track is a named product, but $79 covers the first four-week supply only — $179/mo applies after that, billed $537 per twelve weeks, so the "month" is four weeks. No milligram is published.

Microdose SKU

A named microdose product, priced below its own full-dose plan.

From $69/mo is a named microdose product for four weekly doses, against from $77 for the full-dose plan. Cheaper than the standard plan, but flat within itself — a low starting dose costs what a higher one does — and the page does not say which molecule or billing term the "from" figure buys.

Microdose SKU

Microdose-forward tracks for both molecules, with the visit billed apart.

Both $199/mo figures are the microdose track, and both cover medication only — the provider visit is billed separately on this platform.

Microdose SKU

Board-certified physicians and brand access, with a program fee on top.

$155/mo is a compounded semaglutide microdose against $175 standard — but the $149/mo program fee is charged separately, so the totals stack.

Microdose SKU

A real microdose product line, with the whole price ladder published up front.

Microdose semaglutide and microdose tirzepatide are both $149/mo month-to-month with their own product page and their own four-rung ladder, against $279/mo for the standard compounded tirzepatide.

Microdose SKU

Prices "microdose" and "low-dose" as two different products, not one blurred tier.

The Semaglutide Microdose is a two-month program at $246, which Levers itself states as $123/month. Its Low-Dose program is a separate product quoted from $246/month shipping monthly.

Microdose SKU

Named microdose programs for both molecules — beside a shelf that should not be there.

$197 is a named Semaglutide Microdose Program shown as a sale price against a $591 regular price — and the term each 'from' figure covers is not stated on the card.

Microdose SKU

Microdosing is the whole business — and it argues for it with numbers no trial produced.

The whole practice is physician-titrated microdose tirzepatide, with no full-dose ladder to be upsold onto — but $89 covers the first month only and $199/mo applies thereafter.

Microdose SKUTaking less costs no less

Publishes a real per-dose ladder, then charges a premium for taking less.

The named microdose line is flat at any strength — $199 semaglutide, $229 tirzepatide — which is more than the first rung of its own standard ladder, $189 and $199 at 2.5 mg/wk. Taking less costs more here.

Microdose SKU

A named microdose stack, in two variants, billed on a 4-week cycle.

$179/mo is a purpose-built Microdose GLP-1 stack sold in two named variants — but every Nolu price is billed per four weeks rather than per calendar month, about 8% more across a year than the headline implies.

Microdose SKU

Publishes a milligram ceiling behind every price, then hides the microdose.

$149/mo buys a named microdose semaglutide capped at 0.25 mg, against $249/mo for the full-dose tier capped at 2.4 mg — one of the few rows here where the milligram ceiling is published beside the price. But the microdose SKU is only shown to shoppers whose BMI falls between 20 and 24.9, so most readers are quoted $249.

Microdose SKUTaking less costs no less

A first-class microdose product that costs more than its own standard dose.

The GLP-1 Microdose is $195/mo month-to-month against $185 for the standard semaglutide injection — $10 a month MORE for less drug, and $60 more over three months. Every advertised "starting at" figure on the site is a prepay rung rather than a monthly rate.

Microdose SKUTaking less costs no less

The microdose is the more expensive line item on its own product grid.

The named microdose is $134/mo and sits ABOVE the $127/mo full-dose headline on the same grid — though the $127 is disclosed as a 48-week rung and the $134 carries no published plan length at all, so the two are not the same commitment.

Microdose SKUTaking less costs no less

A real microdose line where every published price is a four-month prepay.

Microdosing Tirzepatide is $159/mo against $139/mo for the general GLP-1 program on the identical four-month plan length, so the microdose line is the premium product. Every published price is a four-month prepay billed in full; the monthly rungs AgelessRx says exist are published nowhere.

Microdose SKU

Two named microdose products, priced under a grid that is entirely introductory.

Two named microdose products priced below their full-dose siblings — $199/mo standing for semaglutide microdose against $299 standard. But the whole grid is discounted under a disclaimer that pricing shown is introductory, and on the full-dose product the multi-month figures are blended averages rather than the rate billed each month.

Microdose SKUTaking less costs no less

Headlines a microdose price that is purchasable at no tier.

$174/mo semaglutide and $224/mo tirzepatide are single-price microdose products with no dose behind them, sold under RxION's own promise of the same price at every dose — so within the microdose range, taking less does not reduce the bill. The $149 headlined on that page is purchasable at no tier.

Microdose SKU

Microdosing costs less here — and is sold only as a three-month prepay.

Microdosing is priced below the standard program — $249 for three months of semaglutide against $149/mo month-to-month standard — but it is sold ONLY as a three-month prepay. There is no monthly rung on the microdose at all, so the cheaper product carries a mandatory term the dearer one does not.

Microdose SKU

A genuinely cheaper microdose tier, billed thirteen times a year.

Its microdose subscription is genuinely cheaper than the standard-dose one on both molecules — $149 against $225 per cycle on semaglutide — but the cycle is four weeks, not a month, so it bills 13.04 times a year and costs about $161 per calendar month. No dose is published for what the microdose buys, anywhere in a catalog of more than a hundred products.

Microdose SKUTaking less costs no less

A dose-scaled tirzepatide ladder beside a flat any-dose semaglutide price.

The named microdose tirzepatide is $245/mo against $249 for the lowest rung of its own published dose ladder — a $4 saving for a dose it does not state. Its semaglutide is sold explicitly as one price for any dose, so a semaglutide microdoser pays the maximum-dose rate.

Microdose SKU

Publishes real milligram bands on both molecules, one of them a microdose band.

Publishes real milligram bands on both molecules: the semaglutide microdose covers 0.25–1 mg/week at $249/mo against $399/mo for the 0.25–2.5 mg all-doses plan, and the tirzepatide microdose covers 2.5–5 mg/week at $349/mo. Only the highest of the three figures in its comparison strip is a month-to-month rate.

Microdose SKU

A microdose page that shows no price — the figure appears only in search results.

The $99 microdose figure is rendered nowhere on the page — it exists only in the page's structured-data markup and a comparison modal — and no billing cycle is attached to it, on a site whose sibling GLP-1 products advertise their twelve-month rung as the headline.

Microdose SKUTaking less costs no less

States the exact dose ceiling behind its microdose price, then charges more for it.

The one row here that states exactly what its microdose price buys: $197/mo caps you at 0.5 mg weekly on a published 0.15 → 0.25 → 0.35 → 0.5 mg titration. It is also $2/mo below the unrestricted plan and $26 MORE across a year, because the first-month credit that applies to the standard plans explicitly excludes it.

Microdose SKU

The clearest microdose price list here, with the flat-price promise scoped away from it.

Four microdose plans priced month-to-month and clearly — $179 and $199 semaglutide, $219 and $229 tirzepatide, against $269 and $349 standard. The flat-price-at-every-dose guarantee is written for the STANDARD plans only, and no milligram figure is published for any microdose tier.

Microdose SKU

Month-to-month microdosing with no commitment tier, and no way to know the molecule.

$129/mo month-to-month, flat at every dose level, and the guarantee is stated for the microdose specifically rather than only for the standard products. But that one price covers four different products — semaglutide or tirzepatide, oral or injection — and the clinician picks which after payment is authorized.

Microdose SKU

A microdose priced beneath its full dose, with nothing published behind either.

Microdose tirzepatide is $249/mo against $279/mo full dose — a $30 gap that is the only thing on the page distinguishing the two, because no milligram, ladder or plan length is published for either. Every GLP-1 figure is a "starting at" price.

Microdose SKUTaking less costs no less

The microdose costs more month-to-month than the standard plan.

The semaglutide microdose is $184/mo month-to-month against $179/mo for standard semaglutide — MORE money for less drug. The site never shows that, because it advertises both at their twelve-month prepay rungs, $79 against $134, where the ordering reverses.

Microdose SKU

A genuinely cheaper microdose, advertised only at its twelve-month prepay rung.

The semaglutide microdose is $199/mo month-to-month against $299 standing for the standard plan, so the low-dose product is genuinely cheaper. Every advertised figure on the site is the twelve-month prepay rung, and the tirzepatide microdose has no monthly option at all — three months paid up front is the floor.

Microdose SKU

Four named microdose products, and no monthly price for any of them.

Four named microdose products, and not one month-to-month price for any of them: every microdose figure is footnoted as paid upfront with a six-month plan or carries no plan length at all. The flat-price-at-every-dose table, which does publish milligrams, covers the standard semaglutide product and is never extended to the microdose line.

Microdose SKUTaking less costs no less

None of the advertised microdose prices exist in its own checkout.

The microdose is charged $99 for the first month and $199/mo thereafter — the identical first charge and identical standing rate as standard compounded semaglutide in Zera's own checkout. None of the $129, $179 or $149 advertised for it exists at any tier.

Microdose SKU

Publishes the dose the price buys — and charges the visit fee again on every refill.

Publishes the dose the price buys, which almost nothing here does: $25 buys a 1.2 mg vial dosed at "20 units once weekly (0.12mg microdose; range 0.1 to 0.25 mg/week)", and $45 buys a 12 mg tirzepatide vial at "5 units twice weekly (0.3mg/injection, 0.6mg/week)". The drug price is not the cost — a flat $39 visit fee recurs on refills, plus $15 shipping.

Microdose SKU

Its "microdose" is three times the standard starting dose per week.

The name describes the injection, not the week. The $149 product is "Microdose Semaglutide + B12 (0.25mg per dose)" given three times weekly, which is 0.75 mg/week — three times the 0.25 mg/week standard starting dose. A reader who reads "microdose" as less drug would be taking more of it than a conventional start.

Microdose SKU

Prices a named starting dose — and never says what period the rate covers.

A dedicated microdosing page pricing a named starting dose: $99.99/mo at 0.25 mg/week semaglutide, $132.99/mo at 1.5 mg/week tirzepatide. Both print a bare "/mo" with NO plan length, billing cadence or commitment stated anywhere on the page — treat them as unverified monthly rates, because an unqualified "/mo" in this category is usually a prepay rung.

Microdose SKU

Sells a named microdose at a lower price — then makes that price flat too.

Two separately named microdose products, one per molecule, priced below the standard plans — $99/month against $129 semaglutide and $169 tirzepatide — each with its own page under /microdosing/. The tier is where the discount stops: both microdose SKUs carry the same "Flat pricing at every dose" badge as the standard products, so a quarter of the microdose still costs $99. No milligram figure is published against the $99, so "microdose" names the product and not the amount. The standard tier states its basis outright: "Unlike clinics that raise fees when doses increase, AHC keeps one flat rate for every dosage tier".

Microdose SKU

Taking less genuinely costs less here — at the tier level, with no milligram behind it.

Two separately named and separately priced microdose programs, one per molecule, each with its own page and FAQ plus a hub at /glp-1-microdose/: semaglutide microdose "starting at $149 per month" against a $199 standard tier, tirzepatide microdose "starting at $189 per month" against $299 — 25% and 37% cheaper. Taking less genuinely costs less at the tier level. No milligram figure is published against any of the four prices, so "microdose" names the product and not the amount, and a quarter-dose cost still cannot be computed. Both microdose figures are "starting at", with nothing explaining what raises them. The FAQ argues against dose-maximizing in its own words: "the emphasis is on identifying your optimal effective dose, rather than pushing toward the highest dose possible".

Microdose SKU

Prices a low dose lower — but the microdose plans stop at twelve weeks.

Three named microdosing products — two injectable, one oral — are priced at $179 per 4 weeks against $249 for the standard semaglutide injection, so a low dose genuinely costs less; no milligram figure is published behind either tier.

Microdose SKU

Sells a named lowest-dose tier with the milligram on the tile, at a lower price.

The Maintenance Program tiers are badged "Therapeutic Microdose" and "Therapeutic starter dose" and carry the milligram on the tile — "Lowest dose only (0.25 mg)" for semaglutide at $139.99/month and "Lowest dose only (2 mg)" for tirzepatide at $179.99/month — priced below the flat tiers, which themselves publish their range: "At Precision Telemed, $249.99/mo is your flat rate from your starter 2 mg dose all the way to the maximum clinical 15 mg dose." The microdose tile also reads "Maintain your current weight", and whether it is open to new patients is not stated.

Microdose SKU

Sells a named microdose for both molecules, and refuses to call four weeks a month.

★★ "Semaglutide Microdose" and "Tirzepatide Microdose" are sold as their own products at $169 per shipment on a 12-week plan, against standard lines at $179 and $269 per shipment. ★★★ It never says "month": prices are quoted per shipment, the annual plan states 13 shipments, and the page says all plans ship on a 4-week cadence — the honest form of the cycle five sellers here disguise.

Microdose SKU

Prices a microdose below its own standard plan, and bills every five weeks.

★★ Microdosing is priced against its own full-dose plan at the SAME term: compounded semaglutide $299 every 5 weeks against $414 every 5 weeks, and tirzepatide $339 against $479. ★ The cycle is FIVE weeks, stated on every plan — about 10.4 charges a year rather than 12, so unlike the four-week cycles here it works in the reader's favor.

Microdose SKU

A named microdosing plan on a branded product, with a membership under every price.

★★ A "Microdosing Plan" sold as its own option on the branded Wegovy oral pill from $149/mo — a named microdose on an FDA-approved product rather than a compounded one. Every figure is a "from" and marked "membership required", so the published number is a floor on one of two charges rather than a monthly total.

Microdose SKU

Prices a microdose at the low end and frames it as metabolic, not weight loss.

★★ A "Microdose GLP-1 Injections Program" priced from $125/mo as its own product — among the cheapest named microdose figures here — and described as "a precision-dosed GLP-1 protocol designed for immediate cardiometabolic and cellular impact" rather than as a discount. Every figure on the site is a starting price and no dose in milligrams is published.

Microdose SKU

Carries a microdosing plan alongside both orals, and prices everything except it.

★★ A "Microdosing" plan carried as its own product — "low-dose GLP-1 customized to your weight loss goals" — beside compounded semaglutide $99/mo, tirzepatide $179/mo and oral sublingual drops from $179/mo. It is the only one of the five products with no price attached, so the low dose can be identified but not costed. Quest labs included; 20 states.

Microdose SKU

Sells a microdose of both molecules as named products, and prices neither.

★★ "Microdosing Semaglutide" and "Microdosing Tirzepatide" are both carried as their own named treatments in the main menu, beside a separate standard weight-loss line. Neither is priced, nor is anything else — while the homepage advertises "upfront pricing" and "no hidden fees" three times over.

Microdose SKUTaking less costs no less

Prices its microdose above its standard GLP-1, openly, in the same grid.

A named "GLP-1 Microdose" at $149/mo sits beside "GLP-1 for Weight Loss" starting at $116 — so THE MICRODOSE COSTS MORE THAN THE STANDARD PRODUCT, openly, in the same grid. Two figures are cited and both are on the page, so the comparison is a reader’s to redo. The standard line shows a struck-through $169 with no end date.

Microdose SKUTaking less costs no less

One all-in price at every dose, and a named microdose line priced slightly above it.

The named semaglutide microdosing protocol is $180/mo against $169/mo for the standard semaglutide injection, which the site says is priced the same at every dose — so taking less costs eleven dollars a month more. No milligram is published behind either figure.

Microdose SKU

A named microdosing program at a fixed low dose that never increases.

★★★ "The GLP-1 Microdosing Program" is sold as its own product with its own price for each molecule — Microdosing Semaglutide $179 and Microdosing Tirzepatide $269 — rather than as a discount on a weight-loss plan. ★★ The dose behavior is stated outright: "offered only at a fixed, low starting dose and does not increase over time", with higher or adjustable dosing directed to a different program. No milligram is attached to "low starting dose", and no standard-dose price sits alongside for comparison. Neither figure carries a billing period.

Microdose SKU

Files a microdose as its own category, and pitches it at muscle not weight loss.

★★ A tirzepatide product filed under its own "Microdose" category — beside Weight Loss and ED Treatment — at $110 for the first month and $129/month thereafter, with both figures printed together. No milligram is attached to the word microdose anywhere, and the product is described as a DAILY plan pitched at lean muscle, stamina and recovery rather than at weight loss, for a molecule normally given once weekly. No standard-dose equivalent is priced beside it.

Microdose SKUTaking less costs no less

Its named microdose costs more than double its own semaglutide headline.

★★★ A NAMED MICRODOSE PRODUCT THAT COSTS MORE THAN THE FULL DOSE. /microdosing prices compounded microdose semaglutide at $249/month and microdose tirzepatide at $198/month, flat, with no term and no code, while /pricing headlines the standard products at $117/mo semaglutide and $198/mo tirzepatide. Set against the standard cards on /pricing, the microdose semaglutide is more than twice the semaglutide headline and the microdose tirzepatide is exactly the tirzepatide headline. Both headlines are discount-code rates on an annual plan — each card also prints the plan price, roughly double — so the comparison flatters the standard product and the microdose still loses it. No milligram is published for any of the four.

Microdose SKU

Names a microdosing program, then sells it as twelve months paid in full.

★★★ A NAMED MICRODOSING PROGRAM — "*12-month Microdosing Tirzepatide program. Paid in full." — which is what this page looks for, sold in the way it most warns against. The advertised $146.25/mo is a YEAR bought in one payment and divided by twelve, against a struck-through $195 for the same program without member pricing. NO MONTHLY RUNG EXISTS, so committing for a year is not the cheap option, it is the only one. And a program named for its dose publishes no milligram anywhere.

Microdose SKU

Its named microdose costs less than its own full dose.

★★★ THE MICRODOSE IS THE CHEAPEST PRODUCT ON THE PAGE — "Microdose GLP-1 — Sub-therapeutic GLP-1 combos — Starting at $134/mo" against compounded semaglutide at $169/mo. Taking less genuinely costs less here, by about 21%, which is the arrangement this ranking looks for and almost never finds. ★ It calls the product SUB-THERAPEUTIC rather than implying a smaller dose does the same job. Every figure is quoted "with annual prepay" and no monthly rung exists for anything. No milligram published.

Microdose SKU

Its low-dose GLP-1 is a catalog line of its own, priced below the standard one.

★★ A LOW-DOSE GLP-1 AS ITS OWN CATALOG LINE, PRICED BELOW THE STANDARD ONE — "Microdose GLP-1 — Low-dose metabolic support — from $129/mo" against "GLP-1 Semaglutide & Tirzepatide — from $149/mo", about 13% less. The second row found anywhere with the microdose cheaper. ★ Described as low-dose metabolic support rather than claiming equivalence. Both are floors, so the saving is between starting points, and no milligram appears on a product named for its dose.

Microdose SKU

Sells only microdose GLP-1s, and publishes no price for any of them.

★★ THE MOST MICRODOSE-FOCUSED CATALOG FOUND ANYWHERE — both products are named "Microdose Semaglutide" and "Microdose Tirzepatide", the section heading is "Microdose GLP-1", and the word appears thirteen times on one page. AND NO PRICE APPEARS FOR EITHER, with both of its pricing pages broken. A reader who has found exactly the product this page exists to help them find cannot learn what it costs. Four-week language ×3, unattached. No milligram.

Microdose SKU

Lists microdosed GLP-1s as named products and prices none of them.

★★ Microdosing is a NAMED CATALOG PRODUCT four times over — "Microdosing Compounded GLP-1 / GIP" and "Microdosing Compounded GLP-1", listed separately for men and for women. And no price appears for any of them: the only figures on the site are in customer TESTIMONIALS, which are reports of individual bills rather than published rates. ★ One real figure is published in the FAQ — recurring lab testing at a stated cost — which is the expense most sellers omit. No milligram.

Microdose SKU

Says its microdose protocol is not for aggressive weight loss.

★★ A named microdose PROTOCOL with a stated purpose and — rarer — a stated NON-purpose: "a lower-dose GLP-1 protocol designed for body composition, metabolic health, and longevity — not aggressive weight loss". Telling a reader what something is not for narrows the market, and most sellers will not. Titration is clinician-directed on a six-month schedule with named support. Every protocol is by consultation and no price appears. No milligram, on a protocol defined by its dose.

Microdose SKU

Puts a microdose GLP-1 in the top-level menu beside the brand-name products.

★ "Microdose GLP-1 Rx" is a TOP-LEVEL catalog item, listed twice — under weight loss and under daily wellness, which reflects the two reasons people take one — beside compounded, oral and brand-name routes in a single navigation. No price appears for any product on the front page. The GLP-1 lines sit inside a broad general-telehealth catalog. No milligram.

Microdose SKU

Sells a longevity microdose as its own program, aimed at preserving lean mass.

★★ "Longevity Microdose" is a program in its own right, listed beside the two molecule programs rather than inside them, described as "low-dose longevity microdosing — calibrated to your biology... never a crash" with outcomes stated as quieted appetite and lean mass preserved rather than a percentage of body weight. That is what a small dose is actually good at. No price for any of the three programs; consultation is the only route. No milligram.

Microdose SKU

A microdose plan priced well under its own semaglutide — with no molecule named.

The $149 GLP-1 Microdose is a plan of its own, a hundred dollars under this seller's own $249 compounded semaglutide — but the microdose never names its molecule and no milligram is published for it, so the low-dose figure cannot be matched to a drug or an amount.

Microdose SKU

Its semaglutide page opens a microdosing intake the site never mentions.

A named "Semaglutide Microdosing" program is offered at $99/mo inside the intake reached from the semaglutide page, against $199/mo published on that page — but no milligram sits behind either figure, and a third intake prices a four-week semaglutide supply at $149.

Microdose SKU

A cheaper microdose on both molecules, billed as an installment on a quarter.

The microdose is a named product on both molecules — $99/mo semaglutide against $129/mo for the standard injectable — and the product pages state "Same Flat Price. No Matter the Dose.", so within a plan the price does not move with the dose. No milligram is published behind either figure.

Microdose SKU

A microdose plan under its own full-dose one, and two headline prices that buy nothing.

Microdose/Maintain is a plan of its own at $219/mo month-to-month against $259/mo for the full-dose Signature plan, and one price covers both molecules on either plan. No milligram is published behind either figure.

Microdose SKU

Sublingual microdoses at the bottom of the catalog, billed every twenty-eight days.

Sublingual microdoses are separately priced products — $149 semaglutide and $199 tirzepatide per 28 days, against $229 and $299 for the standard injectables — with injectable microdoses listed at the same two figures. No milligram is published behind any of them.

Microdose SKUTaking less costs no less

The microdose costs more per cycle than its own full-dose semaglutide.

★★ THE MICRODOSE COSTS MORE THAN THE FULL DOSE HERE: six microdose SKUs are each $179 per four weeks against $169 per four weeks for this seller's own compounded semaglutide. Taking less costs ten dollars more. No milligram is published behind either figure.

Microdose SKU

A microdose program hidden behind a collapsed control, with no molecule named.

A GLP-1 microdose injectable is priced as its own program at $129/mo against $199/mo for the standing semaglutide plan, but it sits behind a collapsed control inside the intake, never names its molecule, and publishes no milligram.

Microdose SKU

A microdose tier on every product, and three answers on what the price covers.

A microdose tier is priced on every GLP-1 product listed — $179 against $217 on the injectable semaglutide, $138 against $212 on the daily sublingual — so the low dose is consistently the cheaper line. No milligram is published, and whether the medication is inside the figure is answered three different ways.

Microdose SKU

Publishes the microgram figure behind its daily oral dose, and three prices for the injection.

The daily oral dose is the low-dose product and it publishes an actual amount: 36 mcg or 145 mcg of semaglutide a day at $169/mo, and 0.4 mg of tirzepatide at $174/mo, both under the $198 and $210 weekly injections. The injection figures are "starting at" floors that the seller says rise with the dose.

Microdose SKU

A cheaper microdose on both molecules, on a table where longer buys nothing.

The microdose is a separately priced product on both molecules — $179/mo semaglutide against $269/mo standard, $259/mo tirzepatide against $369/mo — but its plan-length table prices four, eight and twelve weeks identically. No milligram is published.

Microdose SKU

Its microdose price is the whole site's headline — and is absent from the microdose page.

A separately titled GLP-1 Microdose product priced from $199/mo against from $249 for the semaglutide injection and from $299 for tirzepatide, so the low dose is the cheapest line in the catalog. That $199 appears only on the homepage: the microdose product page itself carries no dollar figure at all, and no milligram is published anywhere.

Microdose SKU

Low-dose is a labeled tier of its own, cheaper than standard on all three products.

Low-dose is a labeled tier of its own holding three products, each priced beneath the standard version of the same thing — $140 against $179 on injectable semaglutide, $140 against $249 on injectable tirzepatide, $179 against $199 on the oral. The price does not change with the dose inside a program, and no milligram is published for either tier.

Microdose SKU

A microdose product per molecule — and on semaglutide the small dose is the dearer one.

Both molecules have their own microdose product with its own ladder: semaglutide $134/mo or $125 on three months, tirzepatide $179/mo or $165 on three, against $149 and $229 month to month for the standard versions. The microdose ladders stop at three months while the standard ones run to six, so the standard semaglutide six-month rung of $114 undercuts the cheapest microdose rung. No milligram is published.

Microdose SKU

A named microdose plan on the branded Wegovy pill, with a membership on top.

The Wegovy Pill Microdosing Plan names its doses: it starts at 1.5 mg a day and stops at 4 mg, where the standard pill climbs to 9 mg and 25 mg. It is priced from $149/mo for the drug alone, the same from-figure as the standard pill, with a separate $149/mo membership on top.

Microdose SKUTaking less costs no less

A separate microdose program, and on one formula it costs more than the full program.

A separate microdose program priced per 12-week supply: $229/mo for the GLP-1 formula against $199/mo for the weight-management version of the same formula, and $239/mo for the dual formula against $249/mo. Neither formula names its drug, and no milligram is published.

Microdose SKU

A separately priced microdose program that never says what drug it is.

A separately titled microdose program at $149 per 4 weeks against $199 per 4 weeks for the weight-loss program. The microdose page names no drug and no milligram, so the lower price cannot be tied to a quantity of anything.

Priced by dose

Prices by the prescribed dose, so the lowest strengths cost the least.

Each GLP-1 product page gives a range across its strengths and says the exact price depends on the prescribed dose: semaglutide injection $119–$229 across 0.25–2.5 mg. The low end is the low dose; the exact figure appears only after clinical review. The tirzepatide injection page shows a $149 headline and no price per strength.

Priced by dose

The one pricing model here that does not charge a low dose like a full one.

Breeze states in its own funnel that every figure is based on the lowest dosage rate and that higher doses may cost more — which is the one pricing basis here that charges by how much drug you actually take.

Priced by dose

An eleven-rung price ladder with a milligram figure against every rung.

Publishes an eleven-rung ladder with a milligram figure against every price: semaglutide is $249/mo at 0.2 and 0.4 mg/week and $349 from 0.9 mg up, tirzepatide $349 at 2.0–4.0 mg/week rising to $649 at 12–14 mg. Read that ladder, not the product-page banners — the "starts at $199" and "starts at $249" claims match no rung of it.

Priced by dose

Sells the vial, states the dose, and lets a smaller dose stretch further.

Prices by the vial with the dose stated: the same $129 vial is a ten-week supply at 0.25 mg/week or a five-week supply at 0.5 mg/week, so the cost per milligram holds and the cost per month falls as the dose does. A separate $49/mo care fee is billed alongside it, putting the all-in cost at 0.25 mg/week near $105/mo.

Priced by dose

Charges by the dose — and measures its discount against the dose above.

A real per-dose ladder, billed monthly: $159 at 0.25 mg/week, $199 at 0.50 mg, $229 at 1.0 mg and $249 at 1.7–2.4 mg, so the bill genuinely falls as the dose does. Read the ladder, not the banner above it — the struck-through "$199" beside the $159 entry price is not a former price of 0.25 mg, it is what Coby charges for the next dose up.

Priced by dose

Quotes a dose below the label start — then bills the "monthly" plan every 23 days.

The new-patient ladder names its milligrams — 0.22 / 0.44 / 0.88 mg across three shipments — and 0.22 mg is below the 0.25 mg/week label start, so the quoted figure really is the lowest-dose rate. Read the CADENCE, not the label: the checkout data bills the "1-month plan" every 23 days and the "quarterly" plans every 83, so a $140 monthly plan recurs 15.87 times a year.

Priced by dose

A full dose-by-dose price table — with the lowest band priced flat.

A full dose-by-dose table across four product lines, every row a 4-week supply with shipping included, reaching down to 0.075 mg sublingual — the lowest published dose here. But the lowest injectable BAND is flat: 0.1, 0.25, 0.35 and 0.5 mg are all $165.90, so taking a fifth of that band's top dose costs exactly what its top dose costs.

Priced by dose

One of the few places where a milligram sits against a price.

The category page prices strength by strength in public, with no quiz: "Semaglutide ODT Tablet (1 mg) $ 199.00 / Semaglutide ODT Tablet (2 mg) $ 299.00 / Semaglutide ODT Tablet (6 mg) $ 499.00", and tirzepatide ODT at 4 mg $299 and 8 mg $499. A low-dose buyer genuinely pays less. The ladder is not linear — per milligram the 1 mg tablet is by far the most expensive item on the page. No pack size, tablet count or day supply is published against any SKU, and the 1 mg tablet is dosed daily, so the price cannot be converted into a monthly or annual cost.

Priced by dose

The full milligram ladder is public, and the starter dose is the cheapest rung.

The pricing page publishes the whole ladder in public with no gate: "Plans are billed every 4 weeks: $224 (2.5mg), $239 (5mg), $249 (7.5mg), $269 (10mg)... 12.5mg ($279) and 15mg ($289) are available for existing patients." The starter dose is the cheapest rung, so staying low genuinely costs less. Read the cycle, not the label: "billed every 4 weeks" is 13 charges a year, so the 2.5 mg plan is $2,912 a year and about $242.67 per calendar month rather than $224. A maintenance tier below the ladder — "from $49 per 4 weeks, with refills at $99 per vial" — appears only in a pricing FAQ answer and has no dose attached.

Priced by dose

Price does follow the dose — but the plan it sells as three months ships twelve weeks.

Tirzepatide is priced by tier and the starter tier is cheaper: "Starter Dose $447 one time payment SAVE $50 $149/ month... Any other dose $697 one time payment SAVE $50 $232/ month". No milligram figure is attached to either rung — they are named "Starter Dose" and "Any other dose" — so a tier cannot be mapped to an amount before purchase. Read the cycle: the plan sold as "3 months" is 12 weeks, so $447 is $161.90 per 4-week cycle rather than the printed $149. Semaglutide refills after the introductory block are $239.00 per 4-week supply, 13 charges a year, against an advertised "$99/ month"; no tirzepatide refill rate is published at all. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Priced by dose

Prints the price of every milligram rung, and names hiding them as the thing it refuses to do.

The tirzepatide ladder is published rung by rung before purchase — 2.5 mg/week $219.99, 5 mg $299.99, 7.5 mg $349.99, 10 mg $399.99, 12.5 mg and 15 mg both $489.99 — and the site names the practice it refuses: "Most companies hide their dosage pricing to get you in the door with the starting dosage. Then increase the pricing on you as you increase the dosage." The starter rung is the cheapest. Semaglutide is priced by month rather than by dose: months 1–3 $199.99, month 4 $229.99, months 5+ $299.99, whatever the patient takes. The semaglutide ladder is labeled in milliliters — ".25-1ml/week Dosage" — while the same site's FAQ writes "(.25-2.5mg)"; the unit on the price table is wrong. GLP-1 service is unavailable in nineteen named states.

Priced by dose

Bills by milligram band, so a low dose is genuinely cheaper — on a six-month lock-in.

Priced by milligram band: semaglutide $199/month standing at 0.25 mg and 0.5 mg, rising to $319 at 1.7 mg and 2.5 mg, and tirzepatide $344 to $719 — a lower dose genuinely costs less, and the advertised figures are the lowest band on a six-month non-cancelable term.

Priced by dose

The medication price really does rise with the dose — and the membership is extra.

"Foundayo self-pay starting at $149/mo for your starting dose and up to $299/mo for higher doses" — the medication price genuinely rises with the dose, though only the two endpoints are published and the $74 clinical membership is charged on top.

Priced by dose

The price actually falls at the low doses — and it is brand-name drug, not compounded.

The Wegovy table prints a price against each dose: pens are $199 at 0.25 mg and 0.5 mg and $349 at 1 mg, 1.7 mg and 2.4 mg; tablets are $149 at 1.5 mg and 4 mg and $299 at 9 mg and 25 mg. GoodRx states the rule outright — "Self-pay pricing varies by dose." There is no compounding relationship here at all: these are coupons against brand-name product at retail counters.

Priced by dose

The price falls at the low doses, and the whole ladder is on the homepage.

The homepage ladder prints a weekly milligram against every monthly price — "GLP-1 dose 0.25 mg per week | $249/mo ~ starting dose" — with five rungs per molecule under the heading "Dosage Options" and no quiz in the way.

Priced by dose

Caps its cheapest product at 1 mg — and never says whether the price is a month or a vial.

The capped products price by milligram ceiling — "Semaglutide Trim Quick Drop — Up To 1 mg - $199 … Semaglutide Trim Shrink and Wink — Up To 2.5 mg - $299" — so more drug costs more. None of the four states a billing period, so the figure cannot be compared with a monthly rate, and a flat "$249 Per Month" tier sits on the same page.

Priced by dose

Publishes a dated dose-by-pharmacy price table, so you can cost your own dose first.

"Compounded medication: paid per fill … Prices below are for a 4-week supply; the pharmacies listed are examples." The matrix prices every semaglutide rung from 0.25 mg to 7.2 mg and every tirzepatide rung from 2.5 mg to 15 mg across five named pharmacies, dated 2026-06-15. The bundled Basic and Premium plans are flat within a stated milligram ceiling instead, so the path decides the answer.

Priced by dose

The price climbs with the dose, so holding low genuinely costs you less here.

Arc-1's own product page says "Semaglutide prices vary depending on dosage and treatment duration", and the ladder behind that sentence is public: $199.99 at 0.5 mg, $249.99 at 1 mg, $549.99 at 2.5 mg on semaglutide, with tirzepatide running $199.99 at 2.5 mg to $399.99 at 7.5 mg. The lowest rung is the cheapest thing it sells.

Priced by dose

Prices by the milligram, sells each month outright, and never makes you subscribe.

The product page prints the whole ladder — semaglutide 0.25 mg $125, 0.5 mg $245, 1.0 mg $295, 1.7 mg $345, maintenance $395 — and each kit is a standalone one-time purchase, so a patient can rebuy the 0.25 mg rung indefinitely. Tirzepatide runs $145 at 2.5 mg to $545 at 15 mg.

Priced by dose

Prices tirzepatide by total milligrams — and the low rung saves you almost nothing.

Tirzepatide is priced against published milligram totals — "Mid Dose Program / 144 mg total / $166 /month / $499 total" against High Dose 216 mg at $549 — so more drug does cost more money, but only barely: 50% more milligrams for 10% more money. The $399 Starter rung publishes no milligram total at all. Semaglutide has a single $199 rung with no ladder.

Priced by dose

Prices by the dose you start at, then holds it.

The price is set by the dose you start at and the pharmacy you pick, then locked: "Choose the dose you start at. Your dose may increase, but your price is fixed at $115." Semaglutide runs $115 at a 0.2 mg start up to $150 at 2.3 mg on the cheapest pharmacy. There is no named microdose SKU, but 0.2 mg is a selectable starting rung and the cheapest thing on the page.

Priced by dose

Charges a published surcharge for the top of the range.

The top of each range carries a published surcharge with milligrams attached: "Our high dose Semaglutide membership offers up to 2.4mg/week (as medically appropriate) for an additional $100 per month", and tirzepatide "up to 15mg/week … for an additional $150 per month". So a low-dose patient genuinely pays the $275 base rate. The milligram ceiling of that base rung is never published.

Priced by dose

A quarter dose costs about a quarter here.

The price is tied to the vial size the weekly dose needs — "Pricing is based on the vial size that matches your weekly dose — no subscription, no hidden fees." Semaglutide at 0.25 mg/week is a 2.5 mg vial at $250 lasting about 10 weeks, or $100/month; at 2.5 mg/week it is a 20 mg vial at $600, or $300/month. Because the step is the vial and not the dose, the ladder inverts locally: 1.5 mg/week ($180/month) costs less than 1.25 mg/week ($200/month).

Priced by dose

Advertises the brand drug at one price and charges twenty times that without insurance.

Stated outright beside both compounded figures: "Varies by dose, available upon evaluation", with semaglutide starting at $155 and tirzepatide at $279. The provider says in its own words that more drug costs more, which makes the quoted price an honest floor rather than a flat rate misrepresented as one — the structure that actually bills a low-dose patient less.

Priced by dose

Names the pharmacy that fills the vial, and marks every product down permanently.

No dose is published behind any figure on this site — not a milligram, not a starting dose, not a ladder — so the quoted price cannot be connected to a quantity of drug at all. Every product is shown as a lower figure beside a struck-through higher one — $99 against $229 for semaglutide, $199 against $349 for tirzepatide — and no ladder, ceiling or per-dose rate is published, so the quoted figure has to be read as an entry price rather than a rate that holds.

Priced by dose

Names the pharmacy that fills every prescription — and prices only the bottom rung.

Every product is advertised "as low as" — compounded tirzepatide, and brand Ozempic, Zepbound and Mounjaro alike. That phrasing prices the bottom of a ladder whose higher rungs are published nowhere, so a patient holding at a low dose is quoted the floor without being told what sits above it. The floor is real and buyable, which separates this from a promotional rate that is not.

Priced by dose

The same tirzepatide carries two different prices on one page.

Every GLP-1 rate is a "Starting at", injectable and sublingual alike, with no second rung published against any of them. The same compounded tirzepatide also carries two different figures in one render — $329/month in one place and "Starting at $283/mo" in another — reproduced on a second fetch, so the floor itself is not stated consistently.

Priced by dose

The only provider here that prices each milligram band — behind a membership you cannot skip.

★★ The seller publishes the ladder itself: compounded semaglutide 0.25–0.75 mg $85/month, 1–1.25 mg $108, 1.5–2 mg $145, 2.25–2.7 mg $183; compounded tirzepatide 1.25–2.5 mg $133, 4–5.5 mg $183, 6–7.5 mg $233, 8–10 mg $258. More drug costs more, in milligrams, stated rather than inferred. All of it requires a $89/month membership, so the lowest band really costs $174/month.

Priced by dose

Publishes a price for every dose band on both molecules.

★★ A full published ladder: compounded semaglutide 0.2–0.25 mg $199/mo, 0.4–0.5 mg $199, 0.88–1 mg $199, 1.5–1.7 mg $299, 2.1–2.5 mg $299; tirzepatide 2.2–2.5 mg $299 rising to $399 at 8.8–10 mg. The pay-ahead column is cheaper at the bottom and DEARER at the top band, which is the reverse of a normal prepay discount.

Priced by dose

Prices three dose tiers per molecule, and charges a consultation before any of them.

Three priced tiers per molecule: semaglutide with B12 $149/mo at 0.25–0.5 mg, $169 at 1.0 mg, from $199 at 1.7–2.4 mg; tirzepatide with niacinamide $349/mo at 2.5–5.0 mg rising to $549 at 12.5–15 mg. A $149 consultation is charged before any medication, and both injectables include an added vitamin.

Priced by dose

Advertises one monthly figure, and its own footnote prices twelve weeks higher.

It states doses in mg per week across three named phases — initiation, therapeutic and maintenance — with 2–2.5 mg/week set against a standard 1–1.5 mg/week, which is more dose detail than most of the field publishes. Its "as little as $199/month" excludes a telemedicine platform fee: the same footnote totals a 12-week program at $699, roughly $233 a month.

Priced by dose

Puts the milligram next to the price, and the supply length next to both.

★★ The dose is on the card with the price: "tablet · 30 day supply", "starting dose (0.8 mg)", $149, with higher-priced options above it. ★ It states a 30-DAY SUPPLY rather than calling four weeks a month — after six sellers here doing the opposite, worth the credit. A separate care fee from $39/mo sits on top.

Priced by dose

Prices every dose of both molecules, and advertises two entry figures of different kinds.

★★ Every rung of both ladders carries a milligram and a price, published before intake: semaglutide $117.96/mo at 0.25 mg through $187.96/mo at 2.5 mg, tirzepatide $178.98/mo at 2.5 mg through $319.98/mo at 15 mg. Holding the lowest dose costs materially less than the top of the same ladder on both molecules. A second, lower entry figure is advertised on the homepage product card — $88.65 — and that one is a three-month block paid in a single charge and divided by three, not a monthly rate. How many weekly injections a "month" contains is not published.

Priced by dose

A printed dose ladder for both molecules, where the lowest rung costs about a third of the top.

★★ A printed ladder on both molecules: semaglutide with B12 at $125 for 0.25 mg rising to $395 at 2.5 mg maintenance, tirzepatide at $145 for 2.5 mg rising to $599 at 15 mg. The lowest rung costs roughly a third of the maintenance rung on each, so holding low genuinely bills low. A kit is four once-weekly injections sold as a thirty-day supply, so a year takes thirteen of them. The semaglutide card is struck through from $599, higher than every rung on its own ladder; the tirzepatide card is struck through from $399, which is the current price of its own 7.5 mg rung.

Priced by dose

One charge for a supply the seller says lasts somewhere between six and eight months.

★ The published figure is explicitly quoted at the starting dose — "6 to 8 month supply at starting dose" — so the dose is what determines how far the charge stretches, and a higher dose exhausts it sooner. What is missing is a fixed denominator: six months makes the block $208 a month and eight makes it $156, and nothing narrows the range. No milligram is published and no molecule is named anywhere on the page.

Priced by dose

Adding ingredients lowers the price here, and every product is permanently struck through.

The catalog card shows a bare figure, but each product page names the dose behind it and re-prices as you change program: plain semaglutide is $192.50 at the 2.5 mg vial, $262.50 at 5 mg and $350 at 10 mg, and tirzepatide runs $210.00 to $402.50 across five programs each labeled "(4 weeks)". Invyncible's own FAQ says outright that cost can go up when the dose increases, so the advertised number is the lowest-dose basis. The period is published for tirzepatide and given as a ~4-5 week dosing example for plain semaglutide; the glycine and B12 programs name their doses but no supply length, and a sibling product names "(2-months)" in its own title. Adding glycine and B12 makes both molecules cheaper than plain, so the formulation list still does not explain the price.

Priced by dose

Publishes a dose-by-duration table where the same charge buys a lower dose for twice as long.

★★★ A published dose-by-duration matrix, which nothing else here offers: $499 buys 1 mg for 20 weeks, 1.5 mg for 16, 1.75 mg for 14, 2 mg for 12 or 2.5 mg for 10 — the same charge, and the lowest rung lasts twice as long as the highest. The higher plan behaves identically at $699 (7.5 mg/16 wk through 15 mg/8 wk) with a $799 tier buying more time again. Every period is in WEEKS and none of the eight lengths is a month. ★★ Every rung carries a milligram AND its molecule: the seller states that its GLP-1 program is semaglutide (0.5 mg rising to 1.7 mg over twelve weeks) and its GLP-1/GIP program is tirzepatide (2.5 mg rising to 7.5 mg), so the receptor labels are mapped rather than left to inference.

Priced by dose

Quotes a starting dose as its own price, and lists retatrutide.

★ A starting dose is quoted as its own line item, apart from the monthly plan, which is the structure that bills a reader for what they actually take. Both published figures are FLOORS — "starting at" and "start at" — and the rungs above them are not published; the page directs a reader to call the office instead. The catalog names retatrutide, which is investigational and unapproved in any form. No milligram appears against any figure.

Priced by dose

The only provider here that prices by milligram, with the milligrams printed.

★★★ THE ONLY ROW HERE THAT PRICES BY MILLIGRAM, with the milligrams printed: semaglutide 1mg $169, 2mg $189, 5mg $209, 10mg $269; tirzepatide 10mg $199, 20mg $239, 30mg $279. A reader can compute cost per milligram, which nothing else on this page permits. ★ And the smallest rung is 37% below the largest, so taking less costs proportionately less. Visits are a second bill — $199 initial, $99 follow-up — published openly beside the drug prices.

Priced by dose

Prices the first three titration doses as their own cheaper pack.

★★★ THE TITRATION DOSES ARE PRICED AS THEIR OWN CHEAPER PACK: "3-Month Starter Pack $399 Total — First 3 titrated doses only" against "3-Month Plan Any Dose $599 total", and $257 against $357 on the other molecule. A reader climbing slowly pays about a third less than one buying unrestricted access. ★ AND THE THREE-MONTH FIGURES ARE TOTALS, not per-month divisions. Syringes and wipes included; 503A named six times. No milligram, on a page built around titration steps.

Priced by dose

Charges a continuing patient less for holding the minimum dose.

The advertised figures are the flat-minimum-dose plans: $99/mo is a continuing patient held at 0.25 mg weekly on a three-month prepay, against $119/mo for the titrating version of the same product. The milligram is printed against every plan, and a first-time patient is offered only the titration price.

Priced by dose

Brand-name Zepbound priced by dose, so the starting dose is the cheapest fill.

Zepbound is priced by strength: $299/mo at the 2.5 mg starting dose, $399 at 5 mg and $449 from 7.5 mg up with timely refills. Taking the lowest dose genuinely costs the least, though Lilly says 2.5 mg is not approved as a maintenance dose.

Flat at every doseTaking less costs no less

A real microdosing program, on a plan that costs the same at every dose.

Compounded plans cost one flat price at every dose, from $169/mo on a 12-month prepay to $289/mo month to month, and the microdosing program has no price of its own, so a low dose costs what a full one does.

Flat at every doseTaking less costs no less

One price at every dose for women's GLP-1 care, with no microdose tier on show.

One price at every dose, "all doses included": from $129/mo semaglutide and $179/mo tirzepatide with no plan length printed, or $199/mo on a 3-month plan. No microdose tier is listed.

Flat at every doseTaking less costs no less

Every billing term published up front, at one price for every dose.

$175/mo semaglutide and $235/mo tirzepatide month to month ($99 and $125 on a twelve-month plan), and the company says every dose costs the same on a given plan.

Flat at every doseTaking less costs no less

One all-inclusive price at every dose, no membership fee.

Eden charges one all-inclusive price at every dose — $99/mo semaglutide, $129/mo tirzepatide, with no membership fee since its 2026 repricing — so a low starting dose costs what a full one does.

Flat at every doseTaking less costs no less

Tablets and injections for both molecules, priced flat, on three-month plans.

MadeMed publishes one figure across semaglutide 0.25–2.4 mg and tirzepatide 2.5–15 mg. Someone deliberately staying at a quarter dose pays what someone at the full dose pays.

Flat at every doseTaking less costs no less

One price for every dosage, and it is not the price it advertises.

Oak's own marketing says "One price · All dosages" and "All doses are the same price", so a starting dose is billed at the top-of-range rate — and no low-dose product is published to move to instead. That one price is $250/mo for semaglutide and $300 for tirzepatide, on the first screen of its order form; the same page read $200 and $250 that morning, so check it before you pay.

Flat at every doseTaking less costs no less

One flat figure at every dose, and no low-dose product to move to.

One product at one figure, the buy box reading "Monthly Supply (All doses)", so a starting dose is billed at $179/mo exactly as a top-of-range dose is — and no microdose protocol or low-dose tier is published anywhere to move to instead. The $99 is the first month only.

Flat at every doseTaking less costs no less

Sells microdosing as its own line — then charges one tirzepatide price whatever the dose.

The tirzepatide plan card states it outright — "Same price regardless of dosage" — so a patient holding a quarter dose pays the full-dose rate. The SEMAGLUTIDE card carries no such line in either direction, so that molecule's dose basis is unstated rather than flat; the row is filed on the molecule that says. The advertised "$59 a month" and "$99 a month" are TWELVE-MONTH rates by the site's own banner ("$59/mo on 12/month Plans"), and no month-to-month figure is published anywhere. A "month" is four weeks — both plans say "shipped every 4 weeks" — so a year is 13 charges. Its eight-SKU microdose line publishes $199/month on 2 SKUs and nothing on the other 6.

Flat at every doseTaking less costs no less

Same price no matter the dose, said three times.

"Same price no matter the dose", repeated in the running header, the plan bullets and the hero, with "no surprise fees as your dose changes" listed among plan inclusions. The month-to-month rungs are $99 semaglutide and $149 tirzepatide; the discount is tied to the term committed to, never to the dose. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

The cheapest medication figure here, with an annual membership underneath it.

One price at every dose: the seller says a provider can personalize to a lower microdose inside the same plan, and because the plan is flat that microdose costs the same $59 semaglutide figure as a standard dose. No milligram is published.

Flat at every doseTaking less costs no less

Says the price never rises with the dose, on a plan that rises at the first renewal.

One price at every dose, stated outright: the treatments questions say the price never increases even as the dose goes up, so a quarter dose is billed at the same $299 semaglutide figure as a full one. No milligram is published anywhere.

Flat at every doseTaking less costs no less

A microdose you can choose at intake, at the same price as not choosing it.

'Microdose' is a selectable dosage type inside the same product at the same from-price, so choosing to take less does not reduce what you pay — and there is no monthly option to leave from.

Flat at every doseTaking less costs no less

Prices everything in public, then charges one figure whatever dose you are on.

The intake collects a weekly semaglutide strength from 0.25 mg up to 2.5 mg, but the price never branches on it — one figure per product per term — so a 0.25 mg patient is billed the same $199/mo as a 2.5 mg patient, and no microdose product exists to buy instead.

Flat at every doseTaking less costs no less

Dedicated micro-dose pages that charge exactly what the full-dose pages charge.

Attaches the words "all doses" to $169/mo semaglutide and $249/mo tirzepatide — one price at every dose — and its dedicated microdose pages charge those identical figures. The microdose discount here is exactly zero, and no dose range is published to bound either claim.

Flat at every doseTaking less costs no less

Says "same price at every dose" in its own words, and sells no low-dose tier.

Prints "same price at every dose" directly beneath $160/mo semaglutide and $199/mo tirzepatide, and publishes no milligram range for the sentence to cover. There is no microdose product to step down to, so a low dose is billed at the full rate.

Flat at every doseTaking less costs no less

Publishes the dose range its flat price covers — so the claim can be checked.

One price whatever the dose, and — rarely — the dose selector publishes the range it covers: 0.25, 0.5, 1, 1.7 and 2.4 mg. That makes the "Same Price All Doses" badge checkable, and the check is damning: hold 0.25 mg and you pay the same $249 as someone taking 2.4 mg. The $158 headline is a twelve-month $1,900 prepay; month-to-month is $249.

Flat at every dose

One of the lowest flat rates here, with no dose published to measure it against.

Its FAQ states a flat monthly rate — semaglutide from $88, tirzepatide from $157, including prescription, unlimited telehealth and shipping. NO milligram figure is published against either price, so "flat at every dose" cannot be falsified and a low-dose patient cannot tell what they are subsidising.

Flat at every doseTaking less costs no less

A quarter dose costs exactly what a full dose costs — and TrimRx says so upfront.

The plan step says it outright — "Same Price. All Dosage Levels." — with "Free Dosage Increases" on every card, so a patient holding 0.25 mg pays the same $299 as one at the top. The advertised $179 is the FIRST SHIPMENT ONLY ($120 off via a code in the entry link); the standing rate is $299 semaglutide, $399 tirzepatide. A "month" is four weeks by its own statement, so the "12-Month Plan" ships 48 weeks, not 52. None of it is reachable without completing the intake — its pricing page renders nothing at all.

Flat at every doseTaking less costs no less

Promises the price won't rise with your dose — then prints three tirzepatide rates.

"Flat-rate pricing — Your price doesn't go up when your dose does" (/treatments), so a quarter-dose semaglutide patient pays the same $119 as a full-dose one. The promise is contradicted on the same site: the tirzepatide product page sells $175 as "New to GLP-1s (starter-dose only). Reg $219", and a rate conditioned on staying at the starter dose is not flat. Three tirzepatide figures — $175, $199 and $219 — all appear as current across three surfaces with nothing reconciling them. A named tirzepatide microdose exists at $99/month, but it is filed under Longevity and the flat-rate promise is not repeated on its page.

Flat at every doseTaking less costs no less

One price at every dose — and it prints the month-to-month rate beside the annual one.

Stated twice in the provider's own words — "Lifetime Price Protection: Same Low Price at Every Dose Level" on the plan card and "Refill price is locked in at the same price ongoing, regardless of the dosage" in the FAQ — so a quarter-dose patient pays the same $199 semaglutide or $299 tirzepatide as one at the top. The headline "Starting at $119 /mo" is an annual prepay, "Paid annually, delivered monthly", 40% below the month-to-month rate — though unusually, both figures sit on the same line of the same card. No milligram figure is published against any price, so the flat claim cannot be checked against a dose range.

Flat at every doseTaking less costs no less

The clearest flat-dose promise on this site, and flat is the wrong direction for you.

Stated more explicitly than anywhere else here, and twice: "Same price at any dose, with no membership fees, no dose-stage upcharges. No hidden fees. Your price stays the same from week one through month six and beyond", and separately "Approved dose changes are included at no additional cost". A quarter-dose patient pays the same $139 semaglutide or $199 tirzepatide as one at the top. The nav headline "From $69" is the first month only, requires code MY70 and is new-customers-only — though it is disclosed on the same card as "Then $139/mo". No milligram figure is published against any price, so the flat claim cannot be checked against a range. The prepay rungs are taken as one up-front charge, and the site says so: "billed upfront", "/mo equivalent".

Flat at every doseTaking less costs no less

Answers the dose question as a plain yes or no — and the answer is no, the price never moves.

Answered as a plain yes/no in the provider's own FAQ: "Does the price increase with the dose? No! All of our medication is available for the same price per dosage." A quarter-dose patient pays the same $149 semaglutide or $299 tirzepatide as one at the top. The cheap figures on the page are new-customer, two-month starter blocks — $74 and $149 per month — and the standing rates are double them, which the site states plainly in its own FAQ. The starter block ships both months in a single shipment, so stopping early does not stop the spend. No milligram figure is published against any price, so the flat claim cannot be checked against a range. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

Flat at every standard dose, with the exceptions named in milligrams and priced.

Stated with its exceptions named, which is rare: "Your price stays flat at every standard dose. The single exception is the maximum dose (2.0 mg/week) at $349/4-weeks. Dose increases are never automatic - your physician approves them, and you confirm the updated price before any charge or shipment." So a quarter-dose patient pays the same $299 per 4 weeks as one just below the maximum, and tirzepatide is $399 through 10 mg/week before rising to $649 at 12.5 and 15 mg. Read the cycle: billing is every 4 weeks — 13 charges a year, so $299 per 4 weeks is $3,887 a year rather than the $3,588 that "$299/month" implies. The homepage banner calls the same figures "One flat monthly price" without the four-week qualifier the product pages carry.

Flat at every doseTaking less costs no less

Publishes every semaglutide strength it offers, next to the one price they all cost.

Stated in one sentence with both prices: "Semaglutide is $299 per month, and Tirzepatide is $399 per month... Your cost remains the same, even as doses change." What makes it checkable — rarely — is that the product page publishes the range the flat rate covers: "Semaglutide Available doses: 0.25 mg | 0.5 mg | 1 mg | 1.7 mg | 2 mg | 2.4 mg". A 0.25 mg patient pays the same $299 as a 2.4 mg one. Read the cycle: the product page calls it a "4 week subscription" three times while the price line says "/ month", so $299 every 4 weeks is $3,887 a year and not $3,588. A featured testimonial is specifically about microdosing tirzepatide, yet no microdose SKU or lower price exists.

Flat at every doseTaking less costs no less

A quarter dose costs what a full dose costs — Amble prints that above the price.

"Same price, every dose" is printed directly above the plan table, and the $179 month-to-month rung does not move with the dose — a quarter dose costs what a full dose costs.

Flat at every doseTaking less costs no less

One price at every dose — and a cheaper tier that buys no medicine at all.

"Uniform cost for all doses." is printed under each price card and repeated in the FAQ — "Regardless of the medication dose for your treatment plan, the price remains the same!" — so a quarter dose costs the same $298 as a full dose.

Flat at every doseTaking less costs no less

Same price at any dose — and the headline rate is a year paid up front.

"Same Price, Any Dose — Your medication costs the same regardless of dosage adjustments" is printed as a numbered feature and repeated in the FAQ as no per-dose escalation, so a quarter dose costs the same $175 as a full dose.

Flat at every doseTaking less costs no less

One rate regardless of dose — and the longer plans do not lower it.

"Then $199/month all-inclusive price, regardless of dose" is printed in the plan module itself, and the standard, glycine and B12 formulations all cost $199 — so a quarter dose is billed like a full dose.

Flat at every doseTaking less costs no less

Same price at every dose — and two different standing rates for one drug.

"Same price, every dose. No hidden fees" is the site's own line, so a quarter dose is billed like a full dose — though the standing rate that rule applies to is quoted as $175/mo on one page and $199/mo on another.

Flat at every doseTaking less costs no less

Same price at every dose, and no published dose behind the price at all.

"Same price, every dose." is printed on the membership cards, so a quarter dose is billed like a full dose — and no milligram figure or vial size is published against $79/month, so the quantity behind the flat rate is not stated either.

Flat at every doseTaking less costs no less

The dose never changes the price — and the price you would pay is not printed.

"The price of medication and ongoing care will never increase from your base plan amount, EVEN if your dosage increases in subsequent months" — one figure at every dose, so a quarter dose costs the same $299 base rate as a full dose.

Flat at every doseTaking less costs no less

One price at all doses, and the advertised rate lasts one cycle.

"ALL doses, ONE low price, NO extra fees!" is printed inside every plan card, on both the introductory and the standing column — a quarter dose is billed like a full dose, and choosing the oral form over the injection does not change it either.

Flat at every doseTaking less costs no less

A flat rate however the dose moves — and the promotional tier never fills up.

"One flat monthly rate, even as your dose increases… no tiered pricing", illustrated with a three-month table showing the dose rising and the price fixed — so a quarter dose costs the same $149 as a full dose.

Flat at every doseTaking less costs no less

Same price at any dose — the disclosure is excellent, the structure is not.

"Your monthly price doesn't jump as your dose increases" — one figure at every dose, so a quarter dose costs the same $279 as a full dose, and no milligram range is published against it.

Flat at every doseTaking less costs no less

Prices a named microdose line below its main program, then runs a waitlist for it.

The price card says "SEMAGLUTIDE $299 /mo All doses included" and "Rate locked for as long as you stay" — one figure whatever the dose. A separate microdosing page prices a named daily-oral line lower, at "$249 / month to month plan", but the same page says "GLP-1 Microdosing will be available nationwide soon! Join the Waitlist Now", so whether that cheaper line can be bought is not established.

Flat at every doseTaking less costs no less

Same price any dose, and the figure it advertises needs six months paid up front.

"Same price any dose" is a bullet inside the price card on both molecule pages, and the teaser footnote repeats the condition attached to it: "*With a 6-month plan. All doses." No milligram figure appears against any rung. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

Same price at every dose, said twice — and the number you see is a twelve-month prepay.

"Same price at every dose" is stated twice on the GLP-1 page, directly beside the plan table. No milligram figure appears against any plan, and the products are named only "Compounded GLP-1" and "Compounded GLP-1 + GIP".

Flat at every doseTaking less costs no less

Runs a flat all-doses plan and a per-milligram vial ladder side by side.

The subscription tiers are labeled "All doses" and the promise is explicit: "All Doses Included. Your cost never increases as your dose goes up, unlike other programs." ★ The exception is the Pay-As-You-Go vials, which are priced by milligram (Semaglutide Plus 5MG $300, 10MG $400, 20MG $550) and sold once, so on that path a smaller quantity does cost less.

Flat at every doseTaking less costs no less

Promises the same price at any dose on four pages, and publishes three different prices.

"Compounded Semaglutide — Same price any dose - $179/mo" on /weight-loss, with "Same price at every dose" repeated on both product pages. No milligram figure appears against any of the three prices the site publishes for the same molecule.

Flat at every doseTaking less costs no less

Publishes the 0.2 mg rung, and charges the 1.2 mg price for it.

"We offer Compounded Semaglutide in 0.2 mg, 0.4 mg, 0.75 mg, 1.0 mg, or 1.2 mg… All doses are priced the same, so your plan is guided by what's medically appropriate, not cost." The strengths are published in full; the price does not follow them.

Flat at every doseTaking less costs no less

Locks your price for life at every dose, and sells one drug at two prices right now.

"PRICE LOCKED FOR LIFE — ALL DOSES INCLUDED", and the subscription plan a buyer actually checks out with is itself named "$149/month – Lifetime Price (All Doses Included)", so the promise carries into checkout. No milligram figure appears against any plan. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

Same price at every dose, and the homepage figure matches no plan on the site.

"Same price at every dose. No hidden fees." sits directly under the price, and the FAQ repeats it: "The same price applies at every dose with no price increases as you titrate up." No milligram figure appears against any of the four plan rungs.

Flat at every doseTaking less costs no less

One price across every titration dose, with the clearest plan disclosure here.

"Same price applies across all titration doses within a plan." Every plan length is published with both the per-month figure and the amount actually charged, but no milligram sits behind any of them. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

One price at every dose, stated outright.

Stated outright on the treatment page: "No membership fees. Same price at every dose. Medication and injection supplies included." The standing rate is $296/month on semaglutide and $359 on tirzepatide, and a quarter dose is billed at that figure exactly as a top-of-range dose is.

Flat at every doseTaking less costs no less

One price at every dose — and it shows you exactly how much of that price is the drug.

The price card itself carries the line "Medication (same price every dose)", repeated as "Every dose is the same price, cancel anytime". The itemized breakdown behind the $174 semaglutide figure shows a fixed $60 medication line that does not move with the dose.

Flat at every doseTaking less costs no less

One monthly figure per molecule with dose changes inside the membership.

KERNX never writes the flat-dose promise as a sentence. It follows from the structure: one monthly figure per molecule — $129 semaglutide, $199 tirzepatide on founding rates, $249 and $299 standard — with "Questions, dose changes, and check ins are part of your membership" and "Personalized titration schedule" listed on both plan cards. Weaker evidence than the providers that state it outright. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

Same price at every dose, with the whole dose ladder printed beside it.

"Same price, every dose. No hidden fees" sits on the plan card with the covered doses printed beside it — semaglutide 0.25, 0.5, 1, 1.75 and 2.5 mg; tirzepatide 2.5 through 15 mg. The month-to-month rate is $249.99 and $349.99, so the 0.25 mg patient pays the 2.5 mg price.

Flat at every doseTaking less costs no less

Says the price is the same at every dose.

Stated on the homepage: "All-inclusive pricing you can trust: your monthly fee covers medical oversight, medication and 24/7 support—no surprise bills ever. Same price, every dose, No hidden fees." The month-to-month rates are $79 semaglutide and $119 tirzepatide, and no milligram figure is published against either.

Flat at every doseTaking less costs no less

One price from the starter dose to the highest.

"All Doses, One Price. $150/mo from your starter dose through your highest dose. No upcharges as your provider titrates you up." The $150 it states that against is the six-month plan at $900 upfront; the month-to-month rate is $219, and the site never repeats the flat-dose promise at that figure. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Flat at every doseTaking less costs no less

The only flat price here tied to named milligram rungs.

Stated against named milligram rungs, which nothing else here does: "We'll lock-in our special lowest cost for all titration doses which include the 1.5 mg, 4 mg, 9 mg to 25 mg." One $349/month figure covers all of them. This is branded FDA-approved Wegovy, not a compounded product.

Flat at every doseTaking less costs no less

Prints the exact milligram range its flat price covers.

The claim is bounded by a published ladder, which is rare: "Semaglutide — From $99 / Month — All doses. Same Price. — 0.25 mg |.5 mg | 1 mg | 1.5 mg | 2 mg | 2.5 mg", and tirzepatide 2.5 through 15 mg. Which figure that flat price actually is remains unsettled — $99, $149 and $179.99 all appear as current on the same page.

Flat at every doseTaking less costs no less

Flat rate no matter the dose, in its own words — so a quarter dose costs what a full one costs.

"Flat Rate Pricing No Matter the Dose" is printed as a line item inside the plan card, so one figure covers each molecule at every dose: $249/month semaglutide and $349/month tirzepatide month-to-month. A quarter dose is billed at the full-dose rate. The $179 and $279 in the banners are first months only.

Flat at every doseTaking less costs no less

One flat price at every dose.

"Two proven options. One flat price. No tiers, no upsells, no insurance games" — one figure per product at every dose, so a quarter dose is billed like a full one. The figure actually attached to a plan is $130/month for the semaglutide injection and $170/month for tirzepatide, matching neither the $113/$136 pair in the homepage comparison table nor the $127/$183 pair on the ongoing-care card of the same page. The flat-dose promise rests on the marketing copy; the plan carries no dose-price line either way.

Flat at every doseTaking less costs no less

Same price for every dose, in its own words — so taking less saves you nothing here.

"Same price for every dose" appears in Velvet's own plan bullets for both injectables, so 0.25 mg is billed exactly as a top dose is. Month-to-month is $159 semaglutide and $249 tirzepatide; the advertised $179 tirzepatide is the first month only, and the advertised $139 and $189 rates are six-month rungs billed at $834 and $1,134 up front.

Flat at every doseTaking less costs no less

One price at every dose — and it is unusually specific about which doses that covers.

"All Dosages are the same price. 2.5mg | 5 mg | 7.5mg | 10mg | 12.5mg | 15mg" — one figure per molecule per term, with no dose dimension in its pricing at all, so a quarter dose is billed at the full-dose rate. Month-to-month is $194.97 semaglutide and $274.97 tirzepatide; the $99.97 and $144.49 printed on the product pages are twelve-month rates, $1,199.64 and $1,733.88 paid up front.

Flat at every doseTaking less costs no less

Says it flat four ways on one page — and leaves one asterisk unexplained.

Stated four ways on one page: "Same price for every dose" as prose under each product, "ALL DOSAGES · Flat monthly pricing" as the plan label above them, and again in the plan copy. A quarter dose costs what a full dose costs, so holding low buys no discount and titrating up costs nothing extra. The nav advertises "from $89/mo*" and the asterisk is never resolved.

Flat at every doseTaking less costs no less

Says the price is the same at every dose, and quotes it three ways on one screen.

Printed on each product card individually — "Same price at every dose" under both semaglutide and tirzepatide. Both cards prefix the figure with "as low as", which is the opposite claim: a floor implies something above it, a flat rate implies nothing moves. The site never reconciles the two, and a third price ($95, for both drugs together) sits in the hero above them.

Flat at every doseTaking less costs no less

The flat-dose promise is in its own page data — and the month it buys is four weeks.

Carried in the site's own page data rather than only in marketing copy: "Price remains THE SAME at all doses". A quarter dose and a full dose cost the same, so holding low buys no discount and titrating up costs nothing extra. The unit is not a calendar month — its own FAQ sells "$299/month" as "a four-week supply of medication", so the flat rate recurs 13 times a year and the annual cost runs about 8.3% above what the "/month" label implies.

Flat at every doseTaking less costs no less

The flat-price promise is real; the month it is priced in is four weeks long.

Stated without qualification on both plan cards: "Same price for ALL doses -- no price increases". A quarter dose and a full dose cost the same, so holding low buys no discount and moving up costs nothing extra. The unit is not a calendar month — the same sentence sells "4 weeks of medication", so the flat rate recurs 13 times a year, and the annual cost is about 8.3% above what the "/month" label implies.

Flat at every doseTaking less costs no less

Flat at every dose, priced per product — and changing its name while you read it.

Claimed twice in the provider's own words — "Same price for every dose" on the homepage and "Your monthly price stays the same at every dose, with no surprise increases" on the tirzepatide page. Each product carries its own published rate rather than a bundled plan, so the flat claim is checkable per molecule. Trading as Polly at the time of the check; the site's own banner reads "Piper is now Polly, same care".

Flat at every doseTaking less costs no less

Promises the same price at every dose, then heads one of its two cards "starting at".

Claimed per product rather than as a site-wide banner — each card's body text reads "All doses just $X/month". The tirzepatide card heads itself "Starting at $249" directly above that sentence, which is the opposite claim: a floor implies something rises above it. The semaglutide card carries no such contradiction. No dose is published behind either figure.

Flat at every doseTaking less costs no less

Says what its billing cycle is, holds the price at any dose, and serves six states.

"Same Price, Any Dose" is printed against both plans, and each card is headed "Billing cycle · Per month" — so unusually for this category, the unit behind the figure is stated rather than assumed. No milligram is published, and the plans are labeled by mechanism ("GLP-1", "GLP-1/GIP") rather than by molecule.

Flat at every doseTaking less costs no less

Prices oral, injectable, branded and compounded — and calls four weeks a month.

Each card states "flat monthly fee — no upcharge based on dose", printed per product rather than as a banner, and the oral capsules repeat it as "no dosage upcharges". The same cards define the fee as buying "4 weekly subcutaneous injections", so the cycle is 28 days and the year holds thirteen of them.

Flat at every doseTaking less costs no less

Advertises one clear price at every dose, then labels all three of its prices "starting at".

The site's pricing promise is "One clear price. Every dose." Every one of its three figures is simultaneously prefixed "starting at" — $149/mo injections, $249/mo tablets, $1,999/mo branded — and a floor and a flat rate are opposite claims. A "$120 OFF" offer runs across the range with no standing rate published.

Flat at every doseTaking less costs no less

Says how many milligrams the money buys, then bills monthly for a 60, 70 or 90-day supply.

★ Every plan publishes a milligram CEILING — "up to 10 mg every 70 days" for the $297/mo semaglutide injection, "up to 180 mg every 60 days" for the $249/mo sublingual tablets — which is more dose disclosure than almost anything here offers. One figure covers any dose up to that cap, so a small dose costs what the top of the cap costs. Billing is monthly while supply runs 60, 70 or 90 days.

Flat at every doseTaking less costs no less

One price at every dose, with the term discounts printed as a plain grid.

★ "All dosages available — same price" is the program heading, over a grid: semaglutide $150/$140/$133 and tirzepatide $199/$189/$179 across one, three and six months. The page states these are per-month prices and that longer plans cost less per month — both the unit and the direction spelled out. No dose is published behind any figure, which matters less here than elsewhere because the price does not move with it.

Flat at every doseTaking less costs no less

Same price at every dose, quoted beside a struck-through figure on every card.

"Same price, every dose" stated beside the figures — semaglutide injections $179/mo and tablets $209/mo. Each sits next to a permanent struck-through higher number ($249 and $279) that nothing explains, and a "save $120/mo on extended plans" claim is made without those plans being priced. No dose published.

Flat at every doseTaking less costs no less

Calls its pricing flat-rate, and applies it to a high starting point.

"Flat-rate pricing" is a stated feature beside free shipping and FSA/HSA eligibility, so the figure should not move with the dose. Compounded semaglutide $297/mo and tirzepatide $367/mo, both above the median here. No dose is published, so the flat claim cannot be checked against a ladder.

Flat at every doseTaking less costs no less

A monthly plan that ships every four weeks, and two different semaglutide figures in one visit.

★ "Same price regardless of dosage" is stated on the product card itself rather than as a site-wide banner, so a quarter dose is billed at the full-dose figure — $149/mo semaglutide, $199/mo tirzepatide. No milligram is published, which is consistent with a flat structure but leaves nothing to check the promise against. The card is headed "Monthly Plan" and states shipments arrive every 4 weeks, so a year takes thirteen of them.

Flat at every doseTaking less costs no less

Promises the same price at every dose, on two products it identifies only by receptor.

★ "Same price at every dose" is stated twice, in the banner and beside the call to action, so a quarter dose is billed at the full-dose figure — $89/mo for the single-target product and $149/mo for the dual-target one. No milligram is published anywhere, which a flat structure does not require but which also leaves the promise uncheckable. Neither compounded product names its molecule; both are labeled by receptor, and this note does not infer a drug from a mechanism.

Flat at every doseTaking less costs no less

Prices both molecules plainly, then scopes its discount two different ways.

★ Pricing is described as flat with no membership, so a quarter dose is billed at the full-dose figure — $229/mo semaglutide and $279/mo tirzepatide as the standing rates, each stated to include the consult and shipping. No milligram is published anywhere, which a flat structure does not require but which leaves the promise uncheckable. A code takes both figures lower and the site scopes it as a first-month saving in one place and an ongoing price in another.

Flat at every doseTaking less costs no less

Two figures, both stamped "any dose" — and neither carries a period.

★ "ANY DOSE" is printed on each program's figure — $149 for the semaglutide program and $189 for the tirzepatide one — so a quarter dose is billed at the full-dose rate by the seller's own statement. The cheaper program reads "starting $149 ANY DOSE", and a floor and a flat rate cannot both describe one number. Neither figure carries a billing period and no milligram is published, so the flat claim cannot be checked against a ladder.

Flat at every dose

Tells you what happens to the price when the dose rises, and never tells you the price.

"Same price, every dose. No hidden fees" is stated outright on the homepage, alongside no monthly membership and cancel anytime — so the dose model is knowable even though the rate is not. The figure it is flat AT is the problem: three discount claims on one page ($299 → $133, a second hidden hero at $299 → $99, and "Get $140 Off Today") do not reconcile, and the section labeled Pricing carries no price at all. No milligram is published.

Flat at every dose

The month-to-month rate is the advertised rate, which almost nothing here manages.

"Same price, every dose" is stated three separate ways, with "Pay month to month" and "no membership fees or surprise price hikes" beside it. ★★ AND THE LADDER RUNS THE RIGHT WAY ROUND — the MONTH-TO-MONTH rung IS the advertised price ($99 semaglutide, $149 tirzepatide), with three, six and twelve months discounting below it, rather than the headline being a twelve-month rate in disguise. It is a dated promotion against a struck-through $299, and the page says so. No milligram is published, so the flat-dose promise cannot be checked against a quantity.

Flat at every dose

Its FAQ and its product cards give different prices for both medications.

"Same price for ALL doses -- no price increases", stated on both product cards. BUT THE PAGE DISAGREES WITH ITSELF ABOUT WHAT THAT PRICE IS: the cards read $149/month semaglutide and $179/month tirzepatide, while the FAQ on the same page reads "a flat $179/month for semaglutide and $259/month for tirzepatide". AND A MONTH IS FOUR WEEKS — "4 weeks of medication" sits inside the inclusion list, so 13.04 charges a year and every figure is ~8.7% dearer annually than its face value. No milligram published.

Flat at every dose

Argues the flat-dose promise instead of asserting it.

★★ The flat-dose promise argued rather than asserted: "Last time, the price went up when the dose went up. What happens here: It doesn't. $189/mo on the 12-week plan is $189/mo at every dose, start to finish." Membership fees are called out as something it does not charge. AND THE PLAN IS TWELVE WEEKS while the price is quoted per month — two different units, stated in the page title, with the total and the number of payments not published. Both pharmacy classes named five times. No milligram.

Flat at every dose

The hero price and the billing table disagree about what one month costs.

"Flat price at every dose — no increase at renewal" covers both the ways a price normally climbs, which is better than most manage. BUT THE HERO AND THE BILLING TABLE DISAGREE: the cards say $139/month and the billing-cycle table prices one month at $199/mo, with three months at $179/mo between them. Nothing marks either as promotional. Every card figure is a floor; no milligram published.

Flat at every dose

Puts the flat-dose promise on every product card, not in a banner.

★ "Same price at every dose" sits on EACH product card rather than in a banner, with the meaning stated in full once — "your cost never goes up as your dosage changes". A promise attached to the product a reader is looking at is harder to miss than one above a page. The same GLP-1 figure appears as a plain rate on the card and as a "from" price in the hero, and the peptide lines are floors while the GLP-1 lines are not. No milligram published.

Flat at every doseTaking less costs no less

Its microdose is a delivery method, sharing one price with the full dose.

THE MICRODOSE IS A METHOD, NOT A PRODUCT — each GLP-1 card reads "CHOOSE A METHOD: MICRODOSE INJECTION / INJECTION" under ONE figure, so semaglutide is $149/mo and tirzepatide $199/mo whichever is chosen. Taking less costs exactly the same, by the page's own construction. ★ Both pharmacy classes named five times each, method choices are real across the catalog, and nobody is charged unless prescribed. No milligram, on a catalog organized by dose size.

Flat at every dose

A permanent limited-time banner carrying the same figure as the standing price.

"Same price at every dose" on both cards and throughout the page — fifteen occurrences across two phrasings — with plain monthly rates rather than floors: $199/mo semaglutide, $299/mo tirzepatide. A "⏰ Limited Time!" banner runs as a PERMANENT repeating marquee carrying the same figure the card gives as standing, so the price is presented as permanent and expiring at once, with no stated reversion. 503A referenced twice; no milligram.

Flat at every doseTaking less costs no less

One price at every dose, sold in three-month blocks that renew every 11 weeks.

One price at every dose, stated as no increase when your dosage changes: $399 per three-month semaglutide plan and $499 for tirzepatide, each renewing every 11 weeks. A small dose costs exactly what a full one does, and no milligram is published.

Flat at every doseTaking less costs no less

One price at every dose, with the milligram range printed, and three prices in play.

One price at every dose, with the range printed: semaglutide 0.5 mg to 2.5 mg at $99.99 and tirzepatide 2.5 mg to 15 mg at $144.97, figures the same page also labels paid annually. A small dose costs what a full one does.

Flat at every doseTaking less costs no less

One low price at any dose, with no plan length printed beside it.

One price at every dose, stated in its FAQ: $89 a month for semaglutide and $139 for tirzepatide, with no plan length printed beside either. A small dose costs what a full one does, and no milligram is published.

Standard dose

Brand-name GLP-1s with two bills, and one pill that costs less at a low dose.

The $149 buys brand Wegovy, pill or pen, at a standard label dose, and the pen costs the same at every dose after a two-month intro; the care subscription is billed separately. There is no microdose product.

Standard dose

All-inclusive monthly pricing for injections and capsules, with no microdose product.

$249/mo month to month buys a standard compounded semaglutide plan, lower on 3- to 12-month plans; no microdose product is priced, so a small dose costs the standard rate.

Standard dose

One price at any dose on a standard plan, with no microdose product.

Sprout sells no microdosing product, so $149/$199 buys a standard plan priced the same at any dose, billed every four weeks; a lower dose would be prescribed within it.

Standard dose

A familiar fitness brand, a real semaglutide discount, and tirzepatide bundles that cost more.

$179 and $209 are month-to-month rates for standard compounded plans with no dose tiers published — and the tirzepatide bundles cost more per month, not less, at three, six and twelve months.

Standard dose

Sublingual drops for a small dose, at a full-dose monthly price.

The $249 sublingual and $297 injectable figures buy a standard semaglutide plan; there is no low-dose product, so a smaller dose is self-directed inside the standard price.

Standard dose

A wide multi-category clinic, but no confirmed microdose SKU.

The $249/mo tirzepatide is billed quarterly at a 60 mg dose, which sits in the standard maintenance range, and neither GLP-1 line is sold as a separately priced low-dose product.

Standard dose

Promises in writing that the price never moves as you titrate up.

Every advertised figure is the twelve-month prepay rung; month-to-month is $259 semaglutide and $349 tirzepatide, and no microdose tier is priced at all.

Standard dose

No low-dose product at all, on a plan billed thirteen times a year.

Sells no microdose or low-dose product at all — compounded semaglutide, tirzepatide and daily tablets only, at $249, $339 and $279 per four-week cycle. The cards advertise entry figures its own FAQ contradicts by up to 67%, and the cycle bills thirteen times a year.

Standard doseTaking less costs no less

The manufacturer own pharmacy — it defines the month, and dates its own price change.

★★ The manufacturer own pharmacy, and it DEFINES the unit — "month defined as 1 box". Self-pay from $149/month at 1.5 mg or 4 mg, with the 4 mg offer dated to end 31 August 2026 and rise to $199. Doses are the approved label doses; no low-dose product exists.

Standard doseTaking less costs no less

Publishes cash prices for six branded GLP-1s, and they are the real ones.

Branded cash prices published per product — Zepbound, Mounjaro and Ozempic around $1,000/mo, Wegovy and Saxenda around $1,300, Victoza around $650. These are the approved products at their label doses; no low-dose product is offered and no compounded route exists.

Standard dose

Names the weekly milligram against the price — and sells its flat rate on a paid-up year.

The $190 per 30-day semaglutide figure names the dose it buys, 0.5 mg a week, and the $239 tirzepatide figure names 2.5 mg a week — both standard starting strengths rather than a microdose, and no low-dose product is sold.

Dose not published

Independently certified, at one flat plan price with no membership underneath.

$190/mo semaglutide and $239/mo tirzepatide are the monthly-plan prices on the company's pricing page, with no dose attached; no microdose tier is priced separately.

Dose not published

A needle-free daily option for both drugs, priced per plan rather than per dose.

$99/mo is the semaglutide buccal-lozenge auto-refill rate with no dose attached; the injection is $129, and tirzepatide is $199 by lozenge and $149 by injection.

Dose not published

The tablet suits a small dose well — nobody will tell you what it costs.

No price appears anywhere on the public site — the pricing page is broken and every product link routes into a two-minute quiz.

Dose not published

Calls the program a microdose and never publishes the dose.

The program is named a microdose and no milligram figure appears on the program page, the plan card or the post-intake checkout — which says only that the final dose and formulation are set by the provider. $199/mo semaglutide and $299/mo tirzepatide are the figures, and neither has a dose attached.

Dose not published

Sells all four formats of both molecules and prices them as one figure.

One "starts at $299 per month" figure covers semaglutide and tirzepatide, tablet and injection alike, and Willow says medication costs vary by dosage, so the figure is a floor with no dose published behind it.

Dose not published

An obesity-medicine visit and a dietitian, with the medication price hidden.

The medication price is shown only after an eligibility request, so no low-dose figure can be confirmed publicly. The $79 is the membership alone.

Dose not published

Oral tirzepatide as well as injectable — but no price before the quiz.

One 'from $199/mo' covers every weight-loss treatment rather than a molecule or a dose; per-dose prices appear only after the intake quiz.

Dose not published

A named microdose tirzepatide product that never says what it costs.

The named compounded microdose tirzepatide carries no published price anywhere on the site. The only visible GLP-1 figure is the $299/mo base semaglutide rate.

Dose not published

Documents itself better than anyone here, and sells no low dose you can buy.

No dose selector appears anywhere before purchase, and the '$199/mo average' is $597 billed every twelve weeks rather than a monthly rate.

Dose not published

Markets flat, transparent pricing on every page and publishes none of it.

Runs a named GLP-1 Microdose protocol whose page carries no price at any tier — it says only that it is available by consultation. The two figures the homepage does show, $149 and $249, are the standard programs, with no plan length, no billing term and no dose attached to either.

Dose not published

Publishes the microdose ladder in milligrams and no price for any GLP-1.

Publishes no price for any GLP-1 product at all — semaglutide, tirzepatide and the microdose protocol each say only "available by consultation", while the peptide catalog on the same site carries per-molecule prices. It does publish the microdose's intended ladder in milligrams, which is the reverse of the usual gap.

Dose not published

Advertises GLP-1 microdosing in the navigation of every page, and it does not exist.

The GLP-1 microdosing item in the site navigation is a dead link that resolves to the testimonials page, so no microdose product or price exists. The $228/mo and $280/mo plans carry no dose, and neither GLP-1 page even names the molecule it sells.

Dose not published

Calls the microdose its differentiator and never prices it on the page.

The GLP-1 Microdose page renders no price — only "available by consultation" — while a $249 figure for it sits unrendered in the site's own code. Three inconsistent price sets ship at once, and the $199/mo advertised site-wide matches no product at any tier.

Dose not publishedTaking less costs no less

The standing price depends on the size of the screen you're reading it on.

No milligram figure appears against any price on the homepage or the GLP-1/GIP product page, so the dose behind the rate cannot be established before purchase. There is not even one price to attach a dose to: the homepage publishes $349/month standing to desktop, tablet and widescreen visitors and $299/month standing to phones, for the same program. The "Simple, Transparent Pricing" cards quote "Starting at $299", which is the introductory first month rather than the standing rate. The microdose page exists but is positioned strictly as post-goal maintenance, with no price of its own.

Dose not publishedTaking less costs no less

Three tirzepatide prices on one page, and no milligram figure on any of them.

Zero milligram figures appear against any price on /weight-loss or /all-treatments, so the dose question cannot be answered before paying. There is not even one settled price to attach a dose to: month-to-month tirzepatide is $449 in one block on the page and $399 in another, and the FAQ on the same page quotes a starting cost of $1299 that matches no card. The site does publish the pre-discount monthly rate beside each first-month offer, which is more than most manage. Every card is badged "Cancel any-time plan" while the refund policy on the same page requires 30 days' notice and deducts a $100 nonrefundable visit and clinical fee. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Dose not publishedTaking less costs no less

Every price on the marketing pages is the twelve-month prepay floor.

The plan set varies only by commitment length — four semaglutide plans, four tirzepatide plans, no dose variants anywhere — so nothing about the price responds to the dose. The site does publish a titration schedule in milligrams ("Month 1 0.25mg … Month 2 0.5mg …", up to 15mg for the GIP product) but attaches no price to any rung. Every figure on the marketing pages is the 12-month prepay floor: "as low as $89/mo" and "as low as $125/mo", against month-to-month rates of $189 and $249 — 112% and 99% higher — and $89/mo means $1,068 taken up front. The absence of dose variants is an absence of evidence, not a flat-price promise; nothing on the site states a dose basis either way.

Dose not publishedTaking less costs no less

A full public price list across four routes, and not one word about what a dose costs.

The site never says whether the price moves with the dose, in either direction, despite listing "Dose adjustments as needed" on almost every tile — the question is unaddressed rather than answered. Reporting anything stronger than "not published" would be a guess. What is published instead is unusually full: four separate routes priced in the open with no quiz — telehealth compounded semaglutide $399/month and tirzepatide $599/month, in-clinic pay-as-you-go $115 and $165 per week, in-clinic packages counted in weeks with the per-week cost printed beside the block price, and brand-name visits at $100/month excluding the drug. The cheapest route requires attending one of fifteen physical locations in Maryland or Virginia weekly; telehealth covers only Maryland, Virginia and Florida.

Dose not publishedTaking less costs no less

Two flat package prices, no milligram anywhere, and three months before you can leave.

Not one milligram figure appears anywhere on the page, and no dose statement of any kind is published in either direction, so the dose question cannot be answered before paying. What is published is two plain package rates with no hedge — semaglutide $299 a month, tirzepatide $399 a month — each including medication, monthly physician supervision and nutrition support. The advertised rate is not month-to-month: "A 3 month subscription is required after which you can cancel at any time", and whether those rates hold after the term is not stated. No week count is published against "a month", so no annual cost can be derived.

Dose not published

Says the price moves with your dose — then never publishes the ladder.

The price card says "(pricing dependent on dosing)" and then quotes a starting figure only. No milligram ladder is published, so what a low dose costs here is not stated anywhere before you pay.

Dose not published

Charges once rather than monthly — and puts no dose behind the price.

One figure per product, "all-in, one-time" for a "~30-day supply", with no milligram amount attached to it: "Your provider sets your exact dose, so yours may vary." Whether a low dose costs less is not stated anywhere.

Dose not published

The published price buys doctor visits, not medicine.

The subscription buys clinical care only — "the subscription cost does not cover medication expenses, which can range from $10 to $900 per month" — so no dose sits behind any published figure and a low dose cannot be costed in advance.

Dose not published

Names the pharmacy behind every price, and never says what dose the price buys.

The pricing page is organized by pharmacy and course length — "Transparent pricing. No hidden fees. Select a treatment to see options for your state." — and carries no milligram figure against any price. Prices differ by compounder for the same drug, but never by dose. No milligram figure is published against this price, so the dose it buys is not stated anywhere a reader can see before paying.

Dose not published

Two clean monthly rates, and not one milligram figure anywhere to measure them against.

Two clean monthly figures — $189 semaglutide, $249 tirzepatide — and no milligram figure anywhere against either. Bionomy's own homepage defers it: "Based on your intake, you'll see a suggested protocol and transparent pricing the same day." Whether the price moves with the dose is not stated in either direction.

Dose not published

No dose sits behind any price here.

No milligram figure appears anywhere — not on the marketing pages, not in the twenty-question assessment, not on the plan screen, where plans are named only as "Semaglutide - 1 Month Plan". The standing rates are $297/month semaglutide and $397/month tirzepatide, with the first month discounted to $197 and $297; the advertised "$49/week" is that discounted first month divided by four. No milligram figure is published against either price, so the dose it buys is not stated anywhere — not on the marketing pages and not at the plan step the assessment leads to.

Dose not published

Only the starting dose is priced, and nothing says what the bill does when you go up.

One product attaches a dose to its price — "Semaglutide Injection", $369, sold by the "Month (.25mg)" — and that is the starting dose. No higher-dose rung is published at any other figure, so there is nothing for a quarter-dose patient to compare against. The sentence on its semaglutide page saying cost will not change with dose sits in copy that repeatedly names two other companies, so it is not treated as Revive's own promise.

Dose not published

Sells the GLP-1 as a daily tablet under the tongue, not a weekly injection.

No dose is published behind either figure — no milligrams and no ladder — and both are quoted "as low as", from $167 for semaglutide and $229.99 for tirzepatide. The route matters as much as the number here: these are daily sublingual tablets, so a fractional dose is whatever product the seller offers rather than something a patient can draw.

Dose not published

The price in the headline is not the price of either drug on the page.

No dose is published behind either figure. Every price is prefixed "Starting at" — semaglutide from $129, tirzepatide from $219 — and the site never says what it starts from: not a starting dose, not a plan length, not a first month. So the quoted price is a floor of unpublished depth rather than a rate that holds. The hero above those cards advertises "from $199/month", which matches neither product.

Dose not published

Calls its pricing transparent, and labels the headline a limited-time offer.

No dose is published behind either figure — no milligrams, no starting dose, no ladder — so neither price can be connected to a quantity of drug. The semaglutide headline also carries a "LIMITED TIME OFFER" label with no standing rate published anywhere, so the durability of the figure is unpublished as well as its dose.

Dose not published

The one published price is labeled, by the site itself, as unconfirmed.

The only figure on the public site is "Plans from $199/mo", annotated on the page itself as "confirmed after provider review" — so it is a floor pending an assessment rather than a quoted rate. No molecule and no milligram is attached to it, and the site publishes no pricing page, no plan page and no page for either medication, so there is nothing for a low-dose patient to compare it with.

Dose not published

A microdose program designed on its own terms, with no price attached to it.

The microdose program has its own page, its own clinical framing and its own candidacy criteria — and no price and no milligram on any of it. "A lower therapeutic dose" and "a fraction of the dose" are the only quantities given. The single public figure, a homepage "$149/mo", is labeled a limited-time offer and is attached to the general GLP-1 pitch rather than to this program, so there is nothing a low-dose patient can compare. ★ Unusually, the gap is not evasiveness about the DOSE — the protocol is described in more clinical detail than most rosters manage — it is a complete absence of commerce on the page.

Dose not published

Sells a needle-free semaglutide lozenge, and prices weight loss by tier instead of by dose.

No figure on the site is attached to a dose. Weight loss is priced in three levels — Level 1 $149, Level 2 $189, Level 3 $399 — and the same Level 1/2/3 structure prices its menopause, longevity and cognitive lines, so the levels describe how much program is included rather than how much drug. ★ It names a "Microdose GLP-1" and sells semaglutide and tirzepatide lozenges, but neither carries a price.

Dose not published

Runs a real microdose program with its own page, and will not put a price on it.

★ A named "GLP-1 Microdose" program is carried as its own treatment with its own page — a real low-dose lane — but it is not priced, and neither full-dose program is either. The microdose page closes with "the Microdose program begins with a conversation". The only public figure is a banner reading "from $199/mo" annotated "confirmed after provider review". Pricing is described as flat-rate with "no dose-change surcharges", which implies a microdose would cost what a full dose does — but with no figure published for either, that is an inference and not a comparison a reader can redo, so it is not recorded as one.

Dose not published

Puts each product's FDA status on its own card, and prices compounded semaglutide lowest here.

No dose is published behind either compounded figure — no milligram, no starting strength, no ladder. ★ Each card does state its own FDA-approval status accurately, with the compounded products marked not approved, which is a disclosure most sellers leave to a footer.

Dose not published

Sells two different products under one identical name, at two different prices.

Two cards carry the identical title "Personalized GLP Injection" at $169/mo and $249/mo with no molecule, no dose and no stated difference between them. Nothing on the site attaches a milligram to any figure, and every card pairs its price with a permanent struck-through higher one.

Dose not published

Halves every price under a limited-time banner, and prints the standing rate beside it.

Every injectable figure is prefixed "Starting at" with no dose published behind it. ★ The standing rate is printed beside the discounted one ($228/mo against $114/mo), which is more than a limited-time headline usually shows — but no end date is published, so when the standing rate begins is unstated.

Dose not published

Built around PCOS, names microdosing as an approach, and names the pharmacies that fill it.

No dose sits behind the $150/month figure, which is itself a "starting at". ★ Microdosing is named as a stated approach — "some patients respond better to smaller, customized dosing rather than standard protocols" — but it is an approach inside the standard price rather than a separately priced low-dose product. The single figure is a "starting at" and the site never claims a flat rate, so whether a microdose ends up costing the same cannot be shown from what is published.

Dose not published

Names the pharmacy that compounds its medication, which most of this category will not do.

One membership figure, "starting at $145", with no dose, no molecule split and no plan length behind it. ★ The compounder is named on the site (Manifest Pharmacy), which is rare here — but naming the pharmacy does not tell a reader what dose the price buys.

Dose not published

Advertises a headline that matches neither drug it sells, and quotes both at two prices.

No dose behind any figure, and the figures do not agree with each other: the hero says "from $199/mo" while the cards price semaglutide from $187 and tirzepatide from $249, and the weight-loss page quotes both at $179. Three numbers for two drugs on one site.

Dose not published

Prices oral tablets the same as injections, and attaches no billing period to either.

No dose behind any figure and no billing period either — compounded semaglutide $225 and tirzepatide $345 are listed as "Regular price" on a supplement storefront with no month, vial or supply length stated anywhere. The oral tablets carry the same two figures as the injections.

Dose not published

Three plans, three starting figures, and no molecule attached to any of them.

Three plans at "starting at $150/month", "$240/month" and "$150/month", none attached to a molecule and none to a dose. The gap between them could be the two drugs, two dose tiers or two service levels; nothing published says which.

Dose not published

Divides a course it calls six to ten weeks into a monthly figure.

What is published is a vial volume rather than a dose — a 1 mL vial of semaglutide or a 2 mL vial of tirzepatide — so no milligram figure appears. The $650 and $750 up-front totals are restated as "$325 per month" and "$375 per month" for what the same paragraph calls a 6–10 week course, so the monthly rate holds at only one point in its own range.

Dose not published

Runs the whole service in Spanish and English, with Spanish-speaking providers.

Compounded semaglutide "starting at $99/mo" and tirzepatide "starting at $169/mo", with no dose behind either. ★ A "Microdose GLP-1" line is carried in the main navigation and described as "the easy way to start", but no page walked publishes a figure for it, so the microdose price is unpublished while the standard ones are not.

Dose not published

Two molecules, two prices, and the six-month rate shown next to each.

No dose behind either figure. Compounded semaglutide $209/mo falling to $178 on six months, tirzepatide $309/mo falling to $263. ★ Both cards show the standing rate and the term rate together rather than replacing one with the other, and neither is struck through or labeled limited-time.

Dose not published

Charges a flat clinical fee for brand-name treatment and lets you buy the medication yourself.

No dose behind the compounded figures, and they are "based on a 2-month supply" rather than month-to-month — a GLP-1 agonist from $95/mo and a dual agonist from $105/mo. ★ Its brand-name plan charges a $25/mo clinical fee with the medication bought separately, so that route has no total the clinic can quote.

Dose not published

Publishes a first-month price for both molecules and no standing rate for either.

Both figures are FIRST-MONTH prices — compounded semaglutide $99, tirzepatide $199 — and no standing rate is published anywhere. A visit charge of $0 to $50 depending on insurance sits on top. No dose behind either figure.

Dose not published

Its two prices are annual-plan rates presented as monthly ones.

$112.49/mo semaglutide and $195.82/mo tirzepatide, both footnoted as requiring an annual plan. The cents are the tell: these are a year divided by twelve, not a monthly charge. No month-to-month rate and no dose is published.

Dose not published

A pelvic-health brand that added a GLP-1 line, and promises the price will not change.

A single "as low as $169/month" with no molecule and no dose attached. ★ The site does commit in writing to no memberships, no monthly fees and no price changes — a durability promise almost nothing else here makes, even though the figure itself remains a floor.

Dose not published

Carries a GLP-1 pricing page in its own navigation and no price on it.

No figure anywhere, including on the GLP-1 pricing page its own navigation advertises. The pages render and the copy is present, so the prices are absent rather than unrendered.

Dose not published

Leads with an AI weight-loss simulator and publishes no price for the medication behind it.

No GLP-1 figure on any page walked. The site leads with an AI simulation of a reader projected outcome and publishes neither the dose nor the cost that would produce it.

Dose not published

Says outright that there are two separate charges, and prices both.

No dose sits behind any figure, and the figures are of two different kinds. ★★★ The page is headed "two separate charges" and prices both — membership $39 first month then $74–$149/mo, plus branded medication at cash price. Naming the structure in a heading is something almost nothing else here does.

Dose not published

Charges for the appointment, not the drug — which makes it cheap and incomplete.

No medication price exists here because no medication is sold — $19.99/mo membership plus $129 a visit buys the clinician, and the prescription is filled at the reader’s own pharmacy. No dose, molecule or drug cost is published, because none is this company’s to publish.

Dose not published

Runs a split-dose microdose plan and publishes no price for it, or for anything else.

★★ The microdose protocol is described precisely — "same medication — half the dose, twice a week" — with tolerance given as the reason and a stated route up to a full plan. No price appears for it or for any plan. Shipping is stated as every 28 days, so thirteen shipments a year rather than twelve.

Dose not published

Publishes peer-reviewed outcomes, and its low figure needs six months up front.

No dose sits behind the figure, and the figure itself is conditional: "6 months of compounded tirzepatide $133 per month", with no month-to-month rate published beside it. ★★ It publishes its own patient outcomes in Obesity Pillars, footnoted as retrospective observational studies — more evidence about its own program than anything else here offers.

Dose not published

Bills your insurance rather than selling you a plan, so there is no price to publish.

No dose and no price, because the program bills insurance rather than selling a plan — stated as in-network with national plans including Medicare. ★ An in-network route matters here: most of the compounded sellers here are cash-only by construction.

Dose not published

A men’s metabolic clinic that prices everything except the GLP-1.

No dose and no price on the GLP-1 line, which routes to a quiz. Its testosterone, metformin, rapamycin and NAD+ lines are each priced from $45 to $149/mo and each marked "medication cost included" — so the absence on the GLP-1 line is a choice rather than an oversight.

Dose not published

Prices both molecules at the low end, and sells them as three-month bundles.

No dose behind either figure. Compounded semaglutide from $99/mo and tirzepatide from $133/mo, both among the lowest here — but both describe three-month starter bundles rather than a single month, and no one-month price is published anywhere.

Dose not published

Low entry figures, all of them floors, with a financing installment among them.

No dose behind any figure, and every figure is an "as low as" — semaglutide from $116/mo, a dual-action option from $199/mo, and a $29 figure that is a financing installment rather than a treatment price. The dual-action product is named by mechanism only.

Dose not published

Quotes the branded drugs at an insurance copay and the cash route separately.

No dose behind any figure. Branded Ozempic, Wegovy, Zepbound and Mounjaro quoted "as low as $25/month" WITH INSURANCE against a $1,349 figure without it — ★ pricing both paths on one page is genuinely useful, but the small number is a copay outcome rather than a price the provider sets.

Dose not published

Every product carries a struck-through price, permanently.

No dose behind either figure. Compounded tirzepatide $399 struck through to $183 and semaglutide $299 struck through to $149 — every product carries the same pairing with no end date published, so the higher number is decoration rather than a rate anyone was charged.

Dose not published

Prices its peptide line below its GLP-1, and quotes every one as a floor.

No dose behind the figure, and it is a "from": semaglutide from $255/mo, above the median here and the highest-priced item in its own catalog, which also lists sermorelin, NAD+, glutathione and MIC+B12 well below it. No tirzepatide price is published at all.

Dose not published

Prices the insured and uninsured paths together, and the small figure is a copay.

No dose behind any figure. Its pricing, FAQ and 27 verbatim sentences are identical to Zealthy and FitRx, each presenting as an independent company. The headline is an insurance copay outcome, and the shared copy attaches a "15-20% average weight loss" trial figure to compounded products.

Dose not published

Publishes a four-figure cash price beside a copay headline for the same drugs.

No dose behind any figure. The third storefront sharing pricing, FAQ and 27 verbatim sentences with Zealthy and Roen Rx. Headline is an insurance copay outcome rather than a price.

Dose not published

Both molecules priced as fixed figures, in the upper half of the field.

No dose behind either figure, but ★ both are single fixed monthly prices rather than floors — compounded semaglutide $225 and tirzepatide $299 — which is rarer here than it should be. Both sit in the upper half of the compounded range.

Dose not published

One entry figure for a doctor-led plan, with neither molecule priced separately.

No dose behind the figure and no molecule attached to it: one "prices start from $189/mo" covers the whole weight-loss program, with an aging line from $150/mo alongside. Nothing published says which molecule the program uses.

Dose not published

Every figure is written per month, and the footnote calls each one a year bought at once.

No dose sits behind any figure, and no figure is a monthly rate either: the site's own footnote defines every per-month number on the page as the per-month cost of a twelve-month program billed upfront. The same footnote says monthly plans exist and prices none of them, so the plan a low-dose reader would buy is unpriced. A "first month from $99" sits beside the annual figures and is a first-month number rather than a rate.

Dose not published

One floor covering both molecules, so the cheaper of the two cannot be identified.

One floor — "plans from as little as $150/month" — covers both molecules, with no ceiling and no milligram behind it. Both drugs are described in detail and neither is priced separately, so the cheaper of the two cannot be identified and nothing says which one the entry figure buys. At other sellers here a dual agonist reliably costs more than semaglutide, which is why a single figure spanning both cannot be true of both.

Dose not published

Two of the lowest figures here, both marked promotional, against a standing rate never printed.

No dose sits behind either figure, and the products are labeled by receptor rather than by drug — one GLP-1 injection at $79/mo and one GLP-1 with GIP at $129/mo. A dual agonist at that price is in practice tirzepatide, but the page does not say so and this note does not infer it. Both figures are written "starting at" and both are promotional: the site's own banner says a summer discount is already applied, and the standing rate is published nowhere.

Dose not published

One GLP-1 product, sold by the quarter, listing three different active ingredients.

The one GLP-1 item in the catalog is sold by the quarter at $299 with no dose attached, and its safety copy lists three active ingredients for that single product — semaglutide, tirzepatide and liraglutide. Three drugs of different potency sold as one item at one price means a buyer cannot tell which molecule the charge buys, let alone at what milligram, so there is nothing a low-dose reader can compare.

Dose not published

Says the medication is inside the service repeatedly, and never says what the service costs.

Nothing is published to attach a dose to: there is no figure anywhere on the public site, and the only path onward collects a name, email address and phone number first. Both molecules are named and both are stated to be compounded, and the medication is stated to be included in the service rather than bought separately — the structure is published and the number is not.

Dose not published

The dual agonist costs a third of the single agonist, which is the reverse of everywhere else.

No dose sits behind either figure, which matters more than usual here because the two figures are three-fold apart in the WRONG direction — the dual agonist at $83/mo against the single agonist at $250/mo, the reverse of the ordering everywhere else. Nothing published explains the gap. The cheaper figure is also a term rate: the page restates it as a yearly total and the FAQ says the rate is locked for the full term, while the terms list monthly and three- and six-month plans without pricing them.

Dose not published

Names its compounding pharmacy, and prices the two molecules twenty dollars apart.

Two figures, $100/mo semaglutide and $120/mo tirzepatide, each priced as its own program. No dose is published behind either one, and nothing states whether either holds as the dose climbs. ★★ The compounding pharmacy is named, which is the check a reader can otherwise never make on a compounded product, and the semaglutide formula is stated to include B vitamins. The semaglutide figure carries an asterisk whose condition the rendered page does not spell out.

Dose not published

A rate advertised as locked for life, on a six-month plan set in the smallest type.

The $125/mo semaglutide figure is advertised as locked "for life" and the condition — a six-month plan — is set in the smallest type on the page. No milligram sits behind it, so the lock is on a number whose contents are unstated, and nothing says whether the locked price follows if the amount of drug changes as the patient titrates. Tirzepatide is named on the product itself and carries no figure anywhere.

Dose not published

Three numbers on one page, and not one of them is a plan price.

No dose sits behind any of the three published numbers, and none of them is a plan price: an insurance copay outcome for branded products, a branded list price used as an anchor, and a compounded cash figure that sits inside a membership structure. Both compounded molecules are named and neither is attached to a milligram or to a statement about what happens as the dose rises.

Dose not published

Writes the addition out — a care fee plus medication, both in the same sentence.

No dose is published behind any figure, and no figure is the whole bill either — a $99/mo care fee sits beside medication priced from $70/mo for compounded semaglutide, $100/mo for tirzepatide and $115/mo for liraglutide, with branded products from $149/mo to $299/mo. Every medication number is a "starting at". The compounded line is described as "personalized dosing for gentler starts", which gestures at a low dose without attaching a milligram or a price to one.

Dose not published

Semaglutide as drops under the tongue rather than an injection, and a candid sourcing note.

The sublingual semaglutide is sold as a 15 mL bottle at $225/mo with no concentration published, so no dose can be derived from it — there is no milligram, no drop count and no way to tell whether a smaller dose makes the bottle last longer. That is the calculation a drops format would otherwise make easiest, and it is the one thing missing. The branded injectables carry no figure at all.

Dose not published

The figure it leads with is labeled a consultation in its own comparison table.

No dose is published behind any figure. The compounded line is $199/mo semaglutide and $249/mo tirzepatide, described as personalized formulations that may include additives such as B12 at the prescriber's discretion. The $149/mo the site leads with is labeled "Consultation" in its own Wegovy comparison table, and no branded medication price appears anywhere, so that route has no total.

Dose not published

Prints the block total beside the divided figure, which almost nothing else here does.

No dose is published behind $179/mo semaglutide or $249/mo tirzepatide. The site's own footnote concedes that "actual prices may vary by dosage and treatment", which concedes the figure moves with the dose without publishing a single rung — so a reader knows the number is conditional and cannot find out on what. ★★ Its three-month option does print the block total beside the divided figure, which is rare here.

Dose not published

Names what the figure covers, and prices the branded pen beside it for scale.

No dose sits behind $149.00/mo semaglutide or $249.00/mo tirzepatide, and both are "starting from" figures with no ceiling. What the page does state is what the figure covers — consultation, medication if prescribed, shipping and support — so the number is whole even though the quantity behind it is not published. The branded pen listed beside them at $1,499.00/mo carries no dose either.

Dose not published

Puts lab work inside the plan rather than billing it as a separate panel later.

One floor — plans from $149/mo — covers both molecules, with no milligram behind it and no ceiling. Both drugs are described in detail, including the mechanism difference between them, and neither is priced separately, so the arithmetic a reader would want is unavailable. ★ Labs are inside the plan rather than billed separately, and the panel is also sold on its own at a one-time $249.

Dose not published

Four products, four prices, all readable before you answer anything.

No dose is published behind $190/mo semaglutide or $239/mo tirzepatide, and both are "starting from". Nothing states whether either price holds as the dose rises, which on a floor with no ceiling leaves the structure underneath unknowable — it is equally consistent with flat pricing, per-dose pricing, or a ladder that steepens.

Dose not published

Prices with no billing period at all, and a four-week cycle disclosed only in the FAQ.

No dose and no billing period: the cards read "Starting at $199.00" for semaglutide and "Starting at $299.00" for tirzepatide with nothing attached to either. The company's FAQ supplies the cycle — dosing weekly for 4 weeks, then a rebill and the next vial — so the unit is four weeks, thirteen times a year, and there is no milligram anywhere to attach a price to.

Dose not published

One of the lower entry figures here, covering both molecules without separating them.

No dose and no molecule behind the figure: one line called GLP-1 treatments from $89/month, with semaglutide and tirzepatide named elsewhere on the site and neither priced. A single floor cannot be true of both at the same cost, because a dual agonist costs more to compound, so either it is the semaglutide number or it buys a configuration the page does not describe.

Dose not published

Prints "plus membership" on every price it publishes, and sells a daily GLP-1.

No dose sits behind the $160/mo liraglutide figure, and that figure is not the bill either — every product on the page is priced "+ membership" against tiers of $25/mo and $155/mo, with a one-time $65 panel to begin. ★ Liraglutide is a DAILY injection, so the practical unit of a dose here is a daily amount rather than a weekly one; the site publishes no milligram for it. Neither semaglutide nor tirzepatide is sold.

Dose not published

Sells a membership, states that medication is not in it, and prints the full commitment total.

No dose is published, and there is nothing to attach one to: no drug is named — the offering is "clinician-prescribed GLP-1 medication" — and the $199/month figure is a membership that the company states excludes prescription medications and lab tests. The only medication figure quoted, roughly $25/month, is an insurance copay outcome dependent on a plan rather than a rate, so it buys no known quantity of any known drug.

Dose not published

Prices a weekly injection by the day, against a first month rather than a standing rate.

No dose is published, and no standing rate either: "from $2.63/day" is the "$79 first month" figure divided by thirty, so both numbers describe the same introductory charge. The drug is a WEEKLY injection, so a per-day price is a denominator the treatment does not have — roughly four charges of medication in a month priced as thirty. The product is described as semaglutide with vitamin B12 and availability is Texas only.

Dose not published

Sells four weeks and calls it four weeks, which is rarer here than it should be.

No dose is published behind either tier, and neither plan card names which molecule it contains — both are named only where the company describes itself. ★★ The billing unit IS published, in the selector: "Choose weeks/plan", option "4 Week", at $199 for Core and $275 for Plus Core. Four weeks is thirteen charges a year, and this seller never calls it a month.

Dose not published

Explains the difference between the two molecules carefully, then prices neither.

One floor — plans from $199/month — covers both molecules, with no ceiling and no milligram behind it. Both drugs are described in detail, including the difference between a single-receptor agonist and a dual one, and neither is priced separately, so the cheaper of the two cannot be identified and nothing says which one the entry figure buys.

Dose not published

At the expensive end of the compounded range, with supervision as what the premium buys.

No dose is published behind the $299/mo entry figure, which is itself a starting point with no ceiling. Both molecules are named as available under one program and neither is priced separately, so the two cannot be compared. The figure is described as covering physician supervision as well as the injections, inside a broader clinic catalog.

Dose not published

Names the standing rate beside its introductory one, then charges medication on top of both.

No dose is published, and the published figure is not the medication at all — $39/mo for a first month and $79/mo thereafter buys the MEMBERSHIP, with medication charged on top and no figure given for it in either molecule, branded or compounded. ★★ Both membership rates are printed with the switch between them explained, which is better disclosure than most intro-rate sellers manage; it just applies to the smaller half of the bill.

Dose not published

Its two largest figures are the claimed worth of free inclusions, not the price of anything.

No dose and no price: the only substantial figures are claimed values of bundled programs given away, $998 and $848, neither of which is anything a reader is charged. ★ The site promises "same price at every dose" emphatically and repeatedly — the structural claim a low-dose reader wants — with no number attached to it, so the promise cannot be checked against anything. No molecule is named either.

Dose not published

Advertises three hundred dollars off a number it does not print.

No dose and no price. The only figure is a $300 discount off a first order the site never prices, so the saving cannot be sized, and every route onward is an eligibility quiz. Both molecules are named as plan options and neither carries a figure or a milligram.

Dose not published

Sold by the year only, with the GLP-1 one line inside a broader optimization protocol.

No dose is published and no molecule is named — the GLP-1 is one line in a protocol alongside sermorelin, NAD+ and a peptide, prescribed after an intake. The $1,500 figure is an ANNUAL membership with no monthly option, and the itemized inclusions are listed at zero without medication appearing among them, so it is not established that the drug is inside the fee.

Dose not published

Its page about keeping costs low prices six things, and none of them is its own treatment.

No dose and no price of its own. Its cost page carries six figures and all describe other programs — about $123 per pound in a survey of commercial plans, roughly $4,000 for thirty pounds, $200 dietitian hours, upwards of $800/month of consultations, $1,000/month for popular plans and $25,000 for surgery. No molecule is named either; treatment is described only as GLP-1-based.

Dose not published

Calls its pricing one hundred percent transparent, and publishes no price.

No dose is published and neither is any price, despite pricing being called fully transparent. The four listed products — a generic GLP-1 line plus branded Mounjaro, Ozempic and Wegovy — carry stock indicators and no figures. What is published is when you are charged, not how much.

Dose not published

Every dollar figure on its weight-loss page belongs to a competitor it names.

No dose and no price for anything Ascend sells: its own products are listed as injection kits with no figures, and the five dollar amounts on the page belong to named competitors in a comparison table. Both molecules are named only in the questions at the foot of the page rather than against a purchasable product.

Dose not published

Prices a dissolving tablet against the injection, for both molecules.

No dose sits behind any of the four figures, all of which are "starting at" with no ceiling: semaglutide injections from $179, semaglutide dissolving tablets from $249, tirzepatide injections from $249 and tirzepatide dissolving tablets from $279. The needle-free route is the DEARER one on both molecules, which is the reverse of how most sellers price it and makes the easier vehicle for a small dose the more expensive one.

Dose not published

The oral form is cheaper than the injection here, on both molecules.

No dose is published behind any of the four figures: oral semaglutide from $179/mo, compounded semaglutide from $199/mo, oral tirzepatide from $199/mo and compounded tirzepatide from $299/mo. ★★ The oral route is CHEAPER than the injection on both molecules. The advertised flat starting figure of $149 is below every product listed, so no purchasable item on the page carries it.

Dose not published

Anchors against a competitor's price in its own hero, and prices consults separately.

No dose sits behind $150/mo semaglutide, $233 tirzepatide or $250 oral tirzepatide. The hero's "$400–600/mo at corporate clinics" is a competitor's price rather than a rung of anything sold here. Consultations are separately priced and one is stated to be required, so the medication figures may not be the whole charge.

Dose not published

Runs three pricing models and says plainly which of them excludes the medication.

No dose sits behind $200/mo semaglutide or $250/mo tirzepatide, which are the compounded program's all-inclusive figures. ★★ The two other routes on the same page are explicitly a clinic fee — $100 initial then $59 per follow-up — with the medication billed by the patient's own pharmacy, so on those routes no medication price exists here at all.

Dose not published

Prices branded GLP-1s including Saxenda, and the pen costs far more than the vial.

No dose and no billing period: the branded cards show bare amounts — Zepbound vial $299, Zepbound Pen $499, Ozempic $349, Saxenda $199 — while a promotional line on the same page states its own term ("$199 for 2 months"), so the omission elsewhere is a choice rather than an implied month. The same drug is priced twice by device, the pen $200 above the vial, which is a device charge rather than a medication one.

Dose not published

Sells a needle-free spray alongside the injections, and prices both molecules identically.

No dose sits behind any of the three figures, all "from" prices with an explicit monthly term: compounded semaglutide from $233.00/month, a tirzepatide with B12 line from $233/month, and a Tirzepatide HypoSpray from $256.33/month. The two injectables are priced identically despite one being a dual agonist, which the page does not explain. ★ The spray is a needle-free metered device rather than a syringe.

Dose not published

Charges per visit and sends the prescription to your own pharmacy.

No dose is published and no medication price exists here at all: the fee is charged per visit and the prescription goes to the patient's own pharmacy, which sets the drug's price. Four products are named as prescribable — Ozempic, Mounjaro, Zepbound and liraglutide — with no figure against any of them, and no dose could be published because the prescribing decision happens after the visit.

Dose not published

A free consultation and a low entry figure, on a product identified only by its receptors.

No dose and no molecule: the product is listed as a compounded GLP-1/GIP injection, named by the receptors it acts on rather than by the drug in the vial, and plans start at $120/mo with no ceiling published. A dual GLP-1 and GIP agonist points at one particular medication in practice, but pointing is not naming and this note does not infer it.

Dose not published

Prices four branded GLP-1s from two manufacturers at one identical four-figure rate.

No dose sits behind $199/month compounded semaglutide or $299/month compounded tirzepatide. Four branded products are each listed at $1999/month, an identical figure across four different drugs. Retatrutide is offered at $399/month — an investigational compound with no approval anywhere and no finished product for a compounder to reference, so no dose or standard for it exists to publish.

Dose not published

Every product struck through, at discounts from a third to four fifths.

No dose and no billing period: compounded semaglutide shows $133 struck from $198 and tirzepatide $166 struck from $247, with bare figures carrying no month, week or supply length. Every product in the catalog is permanently struck through at ratios from about a third to more than four fifths, so the higher figures carry no information about what anything previously cost.

Dose not published

Sells an eleven-week block, which is neither two months nor three.

No dose, and the periods match no calendar unit: the semaglutide starter is "$497 for 11 weeks" and the tirzepatide starter "$797 for 12 weeks", with $149 and $249 shown struck from $199 and $299 and carrying no period of their own. Eleven weeks is neither two months nor three, and the two programs are measured over different lengths, so neither can be normalized against the other or against a monthly rate.

Dose not published

Prices a weekly injection by the week, which is the one denominator that fits it.

No dose sits behind the figure, which is quoted BY THE WEEK — "as low as $25/week". ★ That unit is the treatment's own, since these are once-weekly injections, unlike the per-day pricing seen elsewhere here. It is a floor with no ceiling, and a week is not a month: fifty-two of them is not twelve times four, so a naive annualization falls short by roughly a month.

Dose not published

A clinic chain whose only GLP-1 figure is a floor in a banner.

No dose and no period: the only GLP-1 figure is a banner floor, repeated on no product page, and no molecule is named. A consultation fee is stated and waived on enrollment in a premium program, with the offer stating plainly that the waiver excludes medication — so the medication is a separate and unquantified charge.

Dose not published

Prints the per-month rate and the block total for every term.

No milligram is published against any rung, though the TERMS are unusually well disclosed: one month $299, three months at $283/mo billed $849, six at $249/mo billed $1,495, twelve at $233/mo billed $2,795, with tirzepatide and a transdermal HypoSpray both at $399. A per-day figure ($9.97) also appears, which is the monthly rate divided by thirty on a drug injected weekly.

Dose not published

Prices the oral form and the injection identically, with the month on the figure.

The period is on the figure — $188.00 / month for semaglutide in either form and $238.00 / month for tirzepatide — but no dose the price is keyed to. A concentration (1 mg/1 mL) appears as a selectable option rather than as a quantity the price varies with, and duration options of one, three, six and twelve months are offered. ★ Oral and injectable semaglutide are the same price.

Dose not published

Labels every tier by the supply it buys, and the shortest one is an actual month.

★ The unit is stated plainly — each tile reads "one month supply" against $215 for compounded semaglutide and $320 for compounded tirzepatide, with three-month supplies listed alongside — so the period is clear and an actual month rather than four weeks. No milligram appears anywhere, so what a month's supply contains is unstated.

Dose not published

Writes about GLP-1s at length across the whole site and never quotes a figure.

Neither a dose nor a price appears anywhere on the site, across substantial content about the molecules and how treatment works. The absence was reproduced on two loads with identical page lengths, and there is no store or product interface behind the marketing pages for a figure to be hiding in.

Dose not published

States "billed quarterly" directly on the monthly figure.

No dose and no molecule behind either headline figure, and the per-month numbers are not payable monthly — the page states "billed quarterly" on the same line, so a quarter is the smallest unit and the monthly figure is that charge divided by three. An introductory first-month price is shown separately from the standing rate.

Dose not published

One site-wide entry figure, and neither molecule card carries a price.

No dose sits behind the figure, and neither molecule card carries a price at all — "starting at $99/mo" is the only dollar amount on the site, repeated in the hero and every section header, while the semaglutide and tirzepatide cards describe the drug and attach no figure. Every price is a floor with no ceiling.

Dose not published

Writes the stack out in four words: membership plus medication cost.

No dose and no molecule: the page prints "$99 Membership + Medication Cost" three times, so the medication is a separate and entirely unquantified charge, and two further entry figures appear without being reconciled against that line.

Dose not published

Itemizes every fee and shows the arithmetic on its own discount, which checks out.

No dose and no medication price at all — the published figures are clinic fees (enrollment, a monthly program fee, a three-month plan), each naming the services it covers and none of them the drug. ★ Baseline labs are stated to be inside the enrollment fee.

Dose not published

Sells both molecules as a dissolving tablet and an injection — and the cheaper route flips.

No dose sits behind any of the four figures, all "as low as": semaglutide injectable from $140/mo, semaglutide dissolving tablet from $170/mo, tirzepatide dissolving tablet from $180/mo, tirzepatide injectable from $190/mo. ★★ The cheaper ROUTE flips between molecules — injection cheaper on one, tablet cheaper on the other — so no single rule about format applies across the catalog.

Dose not published

Prints "billed and shipped approximately every four weeks" on every product.

No dose sits behind any figure. ★★ What IS published on every product is the cycle — "billed & shipped approx. every 4 weeks" — so a year takes thirteen charges rather than twelve, disclosed rather than discovered. Branded products carry four-figure monthly cash prices on the same four-week cadence.

Dose not published

Puts the twelve-month condition directly on the figure rather than in a footnote.

No dose, and no monthly rate either: the injection figures are stated "with 12 month bundle" on the figure itself, so they are a year divided by twelve with no shorter term priced. The oral capsules carry a figure and no billing period at all, so the seller's two routes are quoted on incompatible bases.

Dose not published

Names five dispensing pharmacies on the same page as the price.

No milligram appears on the pricing page or on either compounded product, so $129 and $149 cannot be attached to a quantity of drug. ★ What the page does publish instead is rarer and, for a low-dose plan, more useful: five named dispensing pharmacies and a USP 797 beyond-use-date rule limiting an order to ONE VIAL. A reader stretching a vial across a low dose is constrained by that sentence, not by the dose ladder the page omits.

Dose not published

Sells a three-month block and never divides it into a monthly-looking figure.

No dose and no monthly rate. One product, sold as a three-month block for a single payment, with the supply and the support period stated together. ★ The block price is the honest shape here — it is what is actually being bought — but it means nothing on this site can be set against a monthly plan without arithmetic the seller never performs. "Formulation kit" is not defined anywhere on the page, so neither the quantity of drug nor its form is knowable before purchase.

Dose not published

Prints the step from first month to standing rate, then bills its peptides every four weeks.

THE PEPTIDE LINES BILL EVERY FOUR WEEKS, stated on the cards: sermorelin and NAD+ are both quoted "every 4 weeks". Four weeks recurs 13.04 times a year, so an identical figure costs about 8.7% more annually than it would per calendar month. ★ The semaglutide card is the opposite of a trap — it prints the first-month price and the standing rate in one sentence. Tirzepatide is the gap: an initial purchase price with no standing rate beside it. No milligram anywhere.

Dose not published

The advertised price is a membership and buys no medication.

The advertised figure is a MEMBERSHIP and buys no medication. Its own FAQ gives the range and what it covers — medical visits, daily monitoring and coaching — and says the medication is billed separately, with brand-name products routed through insurance and a cash price confirmed only after the consultation. ★ Saying so up front is what separates this from the rows where a second bill is discovered at checkout. No dose is published.

Dose not published

Breaks the care fee into its two parts and states the total.

★★ The most itemized fee here: "$90/month is the physician visit fee. A $10/month fulfillment fee applies to every order, for a total care fee of $100/month", with the medication stated as a separate line "billed separately at our pharmacy's cost". The advertised figure is the SMALLER component, not the standing total. No dose, and no medication price, is published — so the itemization is complete for the fee and empty for the drug.

Dose not published

The medication is inside the advertised monthly figure.

★ Medication is INSIDE the advertised figure — "$195/month with no hidden fees", "includes medication, supplies and unlimited virtual visits" — which removes the two-charge problem most of this category has. Still a floor ("starts at"), with no rung above it published, and a "Save $20/mo" promotion with no pre-discount rate beside it. Compounded semaglutide only. No milligram is stated.

Dose not published

Offers microdosing and twice-weekly dosing by name, and publishes certificates of analysis.

★★ MICRODOSING IS NAMED TWICE — "Twice-weekly and microdosing available", and "individualized dosing based on your response, including microdosing where appropriate" — alongside a claim of third-party testing with a certificates page in the navigation. The price is a BAND (~$80–$135/month) described as bundled care and immediately qualified: cost "varies by medication, dose, pharmacy pricing, and available coverage". One state, in clinic or telehealth. No milligram published.

Dose not published

The price buys a visit and a prescription, and the site says the medication is separate.

The figure buys a VISIT, not a drug, and the site says so: "Visits start at $99. Medication costs are separate and vary depending on treatment and pharmacy." The two published numbers are different units in the same shape — $75/month is a membership rate, $99 is described both as monthly and as per-visit on the same site. Six states only. No dose published.

Dose not published

Itemizes what the monthly fee buys, then charges more for the visit that decides between tiers.

Two monthly tiers, both floors, with an itemized list of what the fee buys — titration, coaching, pharmacy access, quarterly monitoring, direct messaging. The triage visit that decides between the tiers is $299 for thirty minutes, more than a month of either plan. Monitoring is QUARTERLY, which is thin for anyone actively titrating. No milligram published; insurance is not billed.

Dose not published

Bundles labs into the monthly figure, then publishes only a new-patient floor.

★ Labs are inside the advertised figure — "Online visit, labs, and meds shipped" for a single monthly number — which is unusual, since lab cost is the one most often left out of a comparison. Hedged twice: introduced by "From" and labeled a NEW PATIENT OFFER, with no ongoing rate published anywhere. A separate lab-testing catalog makes the bundle's contents ambiguous. No dose published.

Dose not published

Two prices with no billing period attached to either.

NEITHER FIGURE CARRIES A BILLING PERIOD. Semaglutide is "Starting at $266." and tirzepatide "Starting at $399.", both written as sentences with no month, supply length or course attached, so neither can be compared with anything. The route to detail is a paid $1 discovery call. DO NOT ATTACH SKINNYRX'S FDA LETTER TO THIS ROW — see the note in microdose-economics.ts. No dose, pharmacy or cadence anywhere.

Dose not published

Shows the first-month price and the standing rate together on every single line.

★★ THE INTRODUCTORY RATE AND THE STANDING RATE APPEAR TOGETHER ON EVERY LINE — semaglutide $199/mo with $99 first month, tirzepatide $249/mo with $149, NAD+ $169/mo with $119, sermorelin $149/mo with $99. The step a reader would otherwise meet at the second charge is on the card for all four products. Each standing rate is still a floor ("From"), with no rung above published, and no milligram appears against any line.

Dose not published

States its pharmacy class six times and puts the price in the page title.

$190/mo printed in the page TITLE alongside a LegitScript claim, which makes it hard to change quietly. ★ The 503A designation appears six times across the site, more than any other row here states about its own pharmacy class. The figure carries no term, no supply length and no statement of what it includes, so the price is known and what it buys is not. No milligram published.

Dose not published

Medication is inside every figure, and it disclaims affiliation with the brand makers.

Medication is stated as included on every card — semaglutide $199/mo, tirzepatide $399/mo, phentermine $149/mo. ★ An explicit disclaimer of affiliation with the brand manufacturers sits under the products, which most compounded sellers leave to the reader. THE TIRZEPATIDE STEP IS A FULL DOUBLING, wider than the third-to-half spread common here, so the move between molecules should be priced before starting. All three are floors; no milligram published.

Dose not published

Two of the lowest entry prices here, with nothing published above them.

The two lowest entry figures here — $86/mo semaglutide and $125/mo tirzepatide — and BOTH ARE FLOORS with nothing above them published. A price far below the field is usually a genuine low-cost operator, an introductory rate, or the bottom rung of a hidden ladder, and nothing on the page distinguishes the three. Weekly self-injection, doctor-monitored dosing, free shipping and cancel anytime are stated. No milligram published.

Dose not published

Advertises a price-shaped phrase with no price in it.

NO PRICE AT ALL. The only figure is "GLP-1 options for as low as under $100", which stacks a floor ("as low as") on an upper bound ("under") and therefore publishes a boundary rather than an amount — anything from a few dollars to $99 satisfies it. No per-molecule figure, no ladder, no cadence and no dose appears anywhere.

Dose not published

The cheapest membership here, because the visits are billed to insurance.

The lowest membership figure here, $35/mo, and it is a membership: visits are insurance-eligible with named carriers listed, so the fee buys access and continuity rather than the encounter. NO GLP-1 PRICE APPEARS ON THE FRONT PAGE AT ALL, and the membership is a floor besides. A menopause practice first, so a GLP-1 sits inside a wider hormone catalog. No milligram published.

Dose not published

Shows what you are actually charged beside every per-month figure.

★★★ THE BEST PRICE DISCLOSURE FOUND SO FAR: every rung prints the amount BILLED and the interval beside the per-month division — "Billed $675.00 every 3 months — $225.00/mo", "Billed $1,170.00 every 6 months — $195.00/mo". Nearly every prepay trap here works by publishing only the division; this seller publishes the charge too. ★ A month-to-month rung exists and is priced at $330/mo. Both pharmacy classes named six times. No milligram published.

Dose not published

Every price carries its billing period, and two of them are the same number.

Every treatment carries its billing period on the figure — "From $119 · Monthly" — rather than leaving it to be assumed. But the all-inclusive plan price and the semaglutide entry price are the SAME NUMBER, $119, and the page never says whether they are the same product. All figures are floors; no milligram published.

Dose not published

Five different compounds carry exactly the same monthly price.

FIVE UNRELATED COMPOUNDS SHARE ONE FIGURE — NAD+ injection and nasal spray, sermorelin injection and nasal spray, and glutathione are each "As low as $119/mo". Compounds that differ this much do not converge on one price by accident: what is priced is the plan, not the drug. GLP-1 lines are separate at $124 and $174. All seven are floors; no milligram published.

Dose not published

No month-to-month option exists at any price.

NO MONTH-TO-MONTH RUNG AT ANY PRICE. The ladder starts at three months — $249/mo on three, $229/mo on six, $209/mo on twelve — so the shortest thing purchasable is a quarter, which removes exactly the option a reader starting low would want. ★ Microdosing is discussed across the site, which is why the row is here. Every rung is also a floor. No milligram published.

Dose not published

States the commitment and the saving in the same sentence.

★ States the commitment and the saving in one sentence — "Save up to $143 on 6-month plans. Commit longer, save more." — with $169/mo and $152/mo printed side by side rather than one replacing the other. Both are floors, and the six-month rate is a per-month division with no billed amount beside it. 503A named five times. No milligram published.

Dose not published

Its page title and its product card give different starting prices.

THE PAGE TITLE AND THE PRODUCT CARD DISAGREE: the title says GLP-1s from $119/mo and testosterone from $89/mo; the cards on the page say $149/mo and $99/mo. The title is what a search result shows; the card is what a reader finds. Neither is marked promotional and nothing explains the gap. All figures are floors. Published in English and Spanish. No milligram published.

Dose not published

The narrowest gap between the two molecules of any provider here.

Two entry figures visible without an intake — $140/mo semaglutide, $170/mo tirzepatide — and nothing else at all: no ladder, no standing rate, no inclusion list. ★ THE SPREAD IS THE NARROWEST FOUND SO FAR at $30; the usual step from one molecule to the other runs from a third more to a full doubling, which matters to anyone expecting to switch. Both are floors; no milligram published.

Dose not published

Advertises a discount with no price for it to come off.

NO PRICE AT ALL — the only figure is a $200 discount with no rate for it to come off, so a reader learns the saving and never the bill. ★ One thing is stated and worth crediting: a full refund if the intake ends in a decline, so finding out whether you qualify costs nothing. Pay-over-time financing is offered, which is a signal about the size of the unpublished number. No dose published.

Dose not published

Promises one flat payment and no subscription, using a per-month figure.

THE UNIT AND THE PROMISE CONTRADICT EACH OTHER: "$99/mo" sits inside a block reading "One flat payment. No subscription. No hidden fees" and "CoraDoc $99/mo — One payment · no subscription". A per-month figure and a one-payment promise cannot describe the same purchase and the page never resolves which it is. ★ The free tier is unambiguous — visit, shipping and supplies free, full refund if not approved. No milligram published.

Dose not published

Shows the compounded and branded routes together, and prices only one.

Shows the compounded and the branded routes on one page, which is the first real decision in this category and one most sellers force before a reader has seen both. Only one side is costed: compounded semaglutide vials are $149/mo, the branded products are named and priced nowhere. Every figure is a floor. No milligram published.

Dose not published

Three unrelated products carry the same monthly figure.

Three unrelated products share one figure — the dual-agonist GLP-1, NAD+ and glutathione are all $249/month — so the price reflects the plan rather than the compound, and choosing among them is clinical rather than financial. ★ The branded route is handled more honestly than most: a stated $149 consultation charge and no drug price, which makes the split explicit instead of blending it. All figures are floors; no milligram published.

Dose not published

Attaches “including medication” to the figure every time it appears.

★ The words "including medication" are attached to the figure EVERY time it appears — four times, including on both call-to-action buttons. Whether the advertised number covers the drug is the commonest ambiguity here and this page removes it everywhere rather than once in a footnote. It is still a floor with a same-day discount code attached, and no milligram is published.

Dose not published

Its cards and its FAQ state the same two prices, and they agree.

★ Its two figures are stated in the product cards and repeated verbatim in the FAQ, and they AGREE — which sounds like the minimum and is not, since several sellers here contradict themselves between exactly those two places. Neither figure carries a billing period — no month, no supply, no course — so what $99 buys is not established, and a separate "Premium Access" unlock reuses the same number for something else. No milligram published.

Dose not published

Publishes the quarterly charge, its per-month division and a monthly rate together.

★★★ ALL THREE NUMBERS, FOR BOTH MOLECULES: the quarterly charge, its per-month division and the no-commitment monthly rate — semaglutide $409.99/quarter, $136.66/month, $189.99 monthly; tirzepatide $579.99/quarter, $193.33/month, $239.99 monthly. The size of the commitment discount is legible instead of implied. ★ Pausing is offered as well as canceling, and a footnote puts alcohol wipes and syringes inside the price. No milligram published.

Dose not published

Every price on the site is a first-month price.

EVERY PRICE ON THE SITE IS A FIRST-MONTH PRICE and no second month is published anywhere, for either molecule. ★ The qualification is on the FIGURE — the words "first month" travel with the number in the hero, on both cards and in the navigation — so nobody can misread it, which is the honest version of a structure that catches readers elsewhere. But a GLP-1 is not a one-month product, so the entire price list describes the smallest part of the commitment. No milligram published.

Dose not published

Labels the branded figure as membership plus medication rather than blending them.

★ The compounded and branded routes are priced on DIFFERENT BASES and the page labels them: compounded lines are all-in, while the branded line reads "$99 Membership + Medication Cost" with the drug explicitly outside the figure. Most sellers blur exactly this. The consequence is that the lowest number on the page is the one that excludes the medication. All figures are floors; no milligram published.

Dose not published

Makes the all-in claim properly, then discounts from a price it never states.

The all-in claim is in the page title, repeated in the body, and itemized — medication, clinician support, ongoing titration, no membership, free consultation. The same figure appears as $139.99 in most places and $140 in a plan panel, and a $50 discount applies to every plan with NO pre-discount rate published anywhere, so the advertised price is a sale price whose regular version does not appear. No milligram published.

Dose not published

Sells both GLP-1 molecules as daily tablets, with no injection offered.

★ ORAL-FIRST: both GLP-1 molecules are sold as daily tablets with no injectable version beside them, which matters when the needle rather than the cost is the obstacle. Every product carries an in-stock label, unusual and useful on a compounded catalog. No figure carries a billing period at all — not a month, a supply or a course — and no milligram appears, which on a daily oral product is a larger gap than usual.

Dose not published

Offers the branded product with or without insurance, in those words.

★ The branded line is offered "with or without insurance coverage", said in those words, which answers a question readers otherwise have to ask. Neither compounded figure states whether it buys a month, a vial or a course, and the page's own language elsewhere refers to a first VIAL. A new-patient discount runs as a permanent scrolling banner, so no standing rate is published. Microdosing is mentioned twice; no milligram appears to attach it to.

Dose not published

Names every fee it does not charge, and never the one it does.

NO MEDICATION PRICE ANYWHERE. What is published is a list of ABSENCES — no membership fees, consult fee covered, free shipping, FSA/HSA eligible, cancel anytime — each specific enough to hold a seller to, and every one describing a charge the reader will NOT face. The one number that decides whether any of it matters is never given. No ladder, cadence or dose.

Dose not published

Every product on the site bills every four weeks, not monthly.

THE WHOLE CATALOG BILLS EVERY FOUR WEEKS, printed on every product's own figure — tirzepatide $299, semaglutide $199, oral tirzepatide $399, sermorelin $295, each "every 4 weeks". Thirteen periods fit in a year, so each costs ~8.7% more annually than it looks; on the semaglutide line that is roughly $2,595 against $2,388. ★ Credit for putting the cadence on the figure rather than in terms. Every price is also a floor. No milligram published.

Dose not published

Writes the medication charge and the subscription as a sum.

★★ THE TWO-PART PRICE IS WRITTEN AS A SUM — "Cash-pay option: $149/mo + $44/mo provider subscription" — on every card, so the number a reader carries away is the number they pay. Nearly every membership seller publishes the two charges in separate places; this one adds them. Branded catalog only, no compounded option priced. No milligram published.

Dose not published

Publishes what the membership does not cover.

★★ IT PUBLISHES THE EXCLUSIONS — "Shapely memberships do not include: Medications. Labs (typically covered by insurance or $75)" — with a figure on the lab line so a reader can price what is excluded. Nobody else here does that. The consequence: the advertised fee buys video visits and a prescription, the drug is never quoted, and the entry figure is a first-month rate besides. No milligram published.

Dose not published

Promises the price will never increase, and publishes only a starting price.

Two promises repeated throughout: "No price increases — ever" and "No results? No charge", with no membership fee and purity and potency testing claimed. Only an entry figure is published — "Start for $99" — so the price that will not increase is stated for the first month only, which sits awkwardly beside the promise. 503A referenced twice. No milligram published.

Dose not published

Its site-wide starting price is higher than its lead product's starting price.

THE SITE-WIDE FLOOR IS HIGHER THAN ITS LEAD PRODUCT'S FLOOR: "treatments starting at just $157/month" sits directly above compounded semaglutide and tirzepatide "from $145/mo". A floor above one of the things beneath it is not a floor. Both compounding classes referenced twice each. Whole catalog is floors; no milligram published.

Dose not published

The dual agonist costs 84% more than the semaglutide program.

THE WIDEST PROPORTIONAL MOLECULE STEP FOUND SO FAR — $179/mo semaglutide against $329/mo tirzepatide, 84% more, where the category norm runs from a third more to a doubling. Switching molecules is a common path rather than an unusual one, so that step should be priced before starting. Physician oversight and lifestyle coaching named as included in both. Floors; no milligram published.

Dose not published

Prices the visits, says the medication is extra, and takes Medicare.

The figures buy VISITS — "$99 Initial Visit, Follow up visits $75, Plus the cost of medication if prescribed" — with the qualification printed directly beneath the numbers rather than in a footnote. ★ AND IT ACCEPTS INSURANCE INCLUDING MEDICARE AND MEDICAID, rare here and a different calculation entirely for anyone covered. The medication is priced on neither path. Floors; no milligram published.

Dose not published

Prints the renewal rate on the same card as the introductory one.

★ THE RENEWAL IS PRINTED ON THE CARD — "1-Month Plan $249 — For your first month, then renews at $299/mo" — so the step up is visible before starting rather than at the second charge. Which reveals a steep structure: the true month-to-month rate is more than DOUBLE the twelve-month rung ($299 against $129), one of the widest commit-or-not gaps here. Full ladder published; both pharmacy classes referenced; no milligram.

Dose not published

Bills on eight-week cycles while quoting the price per month.

AN EIGHT-WEEK CYCLE — "$149 first month. Then $199/mo on 8-week cycles" — which is neither a month nor a quarter and recurs 6.52 times a year. The figure is described per month on a cycle measured in weeks, and the page does not say which lands when. ★ The first-month and standing rates are both printed, and the inclusion list is specific. A second tier at a higher figure has no stated entry criterion. 503A referenced six times; no milligram.

Dose not published

The lowest all-in figures here, with nothing published behind them.

THE LOWEST ALL-IN PAIR ON THIS PAGE — $83/mo semaglutide and $97/mo tirzepatide, both labeled all-in — and both are FLOORS with no ladder, commitment term or working-dose rate published. Figures that far below the field are usually introductory, committed or the bottom of a dose range, and nothing distinguishes them. ★ The branded line IS written as a sum: "$49/mo membership fee + medication starts at $149/mo". 503A referenced eight times; no milligram.

Dose not published

Quotes its three-month option as a total, not as a monthly division.

★ The three-month option is quoted as a TOTAL rather than divided into a per-month rate — "$179 total for first 3 months" — which is the honest way to present a block and rare here. "No commitment" is attached to the intro figure. But NO ONGOING RATE is published for either molecule after the introductory period, so only the beginning of treatment can be priced. 503A referenced three times; no milligram.

Dose not published

Every price is a first-month price, and the cycle is four weeks.

TWO COMPOUNDING PROBLEMS AT ONCE: every figure is a FIRST-MONTH figure, and the site runs on FOUR-WEEK cycles. So the published numbers describe one discounted four-week period, thirteen of which fit in a year, and neither the standing rate nor the annual cost is derivable from anything on the page. One line is quoted per month rather than per first month, adding a third basis. No milligram published.

Dose not published

Stacks a discount on top of figures that are already floors.

Two floors with a discount stacked on top — "From $149/mo" and "From $224/mo" under a "$99 off your first GLP-1 Treatment Plan" banner — so the figure a first-time reader will actually pay appears nowhere: neither the discounted first plan nor the working-dose rate is stated. ★ Availability is stated as all fifty states, and prescribing is framed as conditional on clinical review rather than automatic. No milligram published.

Dose not published

The only provider here whose pitch is coming off the drug.

★ The only row here whose pitch is coming OFF the drug — "Metabolic recomposition, not another forever prescription" — with off-ramp care and muscle-protective stacks priced as products rather than afterthoughts. Directly relevant to a reader taking a small dose with an exit in mind. Both figures are floors, four-week language appears without being attached to a figure, and no milligram is published. Bilingual; 503A referenced three times.

Dose not published

Publishes the program fee and the medication price in consecutive sentences.

★★ BOTH HALVES OF THE BILL IN CONSECUTIVE SENTENCES: "$99 per month and includes all medical visits, check ins, coaching, advanced program content, and our progress tracking app", then "Medication options are competitively priced, starting at $70 per month". A reader can add them without leaving the page, which is the single most useful thing a two-part seller can do. The medication half is a floor with no ladder above it. No milligram published.

Dose not published

Answers its own asterisk instead of leaving it dangling.

★ IT RESOLVES ITS OWN ASTERISK: the FAQ states the advertised figures are "for eligible patients with a promotion" and that "actual pricing depends on medication". Most sellers print an asterisk and never explain it. The unit is written "/m" rather than "/mo" throughout, which is ambiguous in a category where four-week billing is common. Cancel-anytime ×6, 503A ×3. No milligram published.

Dose not published

Prices by protocol, and its GLP-1 route is entirely needle-free.

★ Prices by PROTOCOL rather than product, printing how many sit behind each category — "2 protocols From $149/mo", "4 protocols From $99/mo". ★ The GLP-1 route is entirely NEEDLE-FREE, sublingual or nasal spray, which is a real route difference. Every multi-protocol figure is a floor and the cheapest category is not the GLP-1 one, which is easy to misread. No milligram published.

Dose not published

Names the B12 in its GLP-1 formulations on the card.

★ Names the FORMULATION on each card — both GLP-1 lines are compounded with B12 and the page says so, where several sellers describe an identical product as the plain molecule. None of the four figures carries a billing period, so the products can be ranked against each other and none of them costed. All floors. No milligram published.

Dose not published

Prices its NAD+ per treatment, with arithmetic you can check.

★★ THE CLEAREST COST PRESENTATION FOUND: NAD+ priced per treatment and per course — "1000mg (40 treatments) $249 (supplies included)" against "$59 per shot" in a clinic — with arithmetic a reader can check, because forty for $249 IS about $7 each. Doses, not months, is the right unit for a peptide. The clinic comparison is unsourced, both asterisks go unexplained, and the GLP-1 line is not priced this way. No milligram for the GLP-1.

Dose not published

Runs a template that appears on other sites, at a much higher starting price.

Built on a MARKETING TEMPLATE that appears on at least two other sites reviewed here — the same "$140 Off Today", the same wait-times tagline, the same delivery promise — with different prices attached. That is a shared template, NOT evidence of a shared operator; nothing published by any of them names a common entity, and this row asserts the resemblance only. Its starting figure is well above the others using the layout. No milligram published.

Dose not published

States its pharmacy standard fifteen times and its price not once.

NO PRICE ANYWHERE — the only figure is a "$150+" free-shipping threshold. ★ What it does publish is its pharmacy position, fifteen times: the 503A designation with named sections for provider network, pharmacy and quality, and source standards. More attention to the compounding question than any other row here. But nothing about cost, molecule or cadence can be learned. No milligram published.

Dose not published

Prices its longevity line and leaves the weight-loss line blank.

THE PRICED CATEGORY IS THE WRONG ONE for most readers arriving here: longevity and cellular health from $99, while the weight-loss line carries no figure at all and is described in terms of tailoring. First-month language appears four times with no number attached to any of it. So what a GLP-1 costs cannot be determined from the site. No milligram published.

Dose not published

Publishes a comparison table with figures in both columns.

★ Publishes plain monthly rates for five products without an intake — semaglutide $119/mo, tirzepatide $229/mo, NAD+ $115/mo, sermorelin $115/mo — with monthly and three-month views. Beside them runs an UNSOURCED competitor column headed "the other guys", naming nobody and attributing figures to no one, so it records what the seller wants believed about the market rather than anything checkable. Read the left column. No milligram.

Dose not published

Publishes the committed rate, the month-to-month rate and the saving together.

★★ THREE NUMBERS IN ONE LINE: "STARTING AS LOW AS $89/mo — $199/mo month-to-month — save $660 with a 6-month plan". The committed rate, the no-commitment rate and the saving as a DOLLAR TOTAL rather than a percentage, so the trade is evaluable at a glance and the arithmetic is checkable. The month-to-month rate is more than double the headline. ★ No charge until approval, with the hold released automatically. No milligram.

Dose not published

Argues against the membership model with figures rather than adjectives.

★ Argues with numbers rather than adjectives: "Many GLP-1 programs charge $39 to start, then $149/month just to stay a member. We don't." against its own "$162/month, $0 membership fee, medication included". The structure it describes genuinely exists elsewhere, so the comparison is checkable as a pattern. It names no seller, and its own figure is a floor. No milligram published.

Dose not published

Will not restart your titration from week one if you switch to it.

★★ BOTH RUNGS ON EVERY CARD — semaglutide "From $89/mo — From $174/mo month-to-month", tirzepatide "From $133/mo — From $250/mo month-to-month" — so the commit-or-not gap is visible without a checkout. ★★ AND THE TITRATION POLICY IS PUBLISHED: a switching patient is continued "at or near your current titration level", not restarted from week one, which is the sentence that matters most to anyone moving providers mid-course. "Lock in your price for life" covers renewals as well as dose increases. Floors; no milligram.

Dose not published

Prices both molecules before the intake, on terms that name no company at all.

The $249 semaglutide and $349 tirzepatide month-to-month rates are readable before the intake, and no milligram is attached to either of them or to any prepay rung — so what dose the figure buys is not published.

Dose not published

Promises the quoted price is the price you pay, on pages that quote no price.

All three GLP-1 pages print "AVAILABLE BY CONSULTATION" where a figure would sit, so no price is published at any dose, and the GLP-1 Microdose is sold without naming its molecule or its milligram.

Dose not published

Names neither molecule publicly — the drug appears after your address is collected.

Nothing on the public pages names a molecule or a milligram; the $199 semaglutide and $369 tirzepatide plans and their doses appear only after name, email, phone and shipping address have been collected, so no dose sits behind a published figure.

Dose not published

Names six pharmacies and two prescribers, and publishes no cancellation terms at all.

The two published figures are "as low as" floors with no billing period, no dose and no milligram attached, and the month-to-month rates are not published where a reader can reach them at all.

Dose not published

One figure with no billing period, and everything else behind an account.

The single published figure, $185, carries no billing period, no drug and no dose — it is a floor on a personalized GLP-1 treatment, and no milligram is published for any product.

Dose not published

Four prices on one page, and a tirzepatide plan sold only three months at a time.

The semaglutide page carries four different figures and the tirzepatide plan is quarterly only, and no milligram is attached to any of them — so no dose sits behind any price this seller publishes.

Dose not published

Prescribes GLP-1s inside hormone care, with no GLP-1 price anywhere.

No GLP-1 price is published at all, so no dose sits behind any figure. The $149/mo self-pay membership buys visits only; medication is billed separately by your pharmacy, your insurer or its own compounded line.

Dose not published

A prescription to your own pharmacy, with no plan, no membership and no drug sold.

No medication is sold and no consultation fee is shown before the request form, so no dose sits behind any figure. The drug is bought at your own pharmacy at a label dose of a branded product.

Dose not published

Both molecules as an injection or an under-the-tongue tablet, from one unspecific price.

The from-$199/mo figure is not attached to a molecule or a dose, and the standing rate for each drug is shown only after intake. No low-dose product is sold, and no milligram is published.

Dose not published

Starting prices with no plan length beside them, in ten states.

Starting at $129 for semaglutide and $399 for tirzepatide, with no plan length and no dose attached to either. Dose and titration are set by the provider after intake, and no low-dose product is sold.

Dose not published

Pay per visit, and the prescription goes to your own pharmacy.

Only visit fees are published ($195 for the first, $159 per follow-up). No medication is sold, so no dose sits behind any figure; the drug is bought at your own pharmacy at a label dose.